

# CITATION REPORT

List of articles citing

**A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid**

**DOI: 10.1038/ng0892-345**  
**Nature Genetics, 1992, 1, 345-7.**

**Source:** <https://exaly.com/paper-pdf/23529037/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1313	Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. <b>1992</b> , 258, 668-71		805
1312	Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. <i>Nature Genetics</i> , <b>1992</b> , 2, 157-60	36.3	142
1311	Alzheimer's disease. In search of the soluble. <b>1992</b> , 359, 268-9		31
1310	Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. <b>1992</b> , 360, 672-4		1594
1309	Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. <i>Nature Genetics</i> , <b>1992</b> , 2, 335-9	36.3	291
1308	A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. <i>Nature Genetics</i> , <b>1992</b> , 2, 340-2	36.3	246
1307	Biochemistry of Alzheimer's disease amyloid plaques. <b>1993</b> , 26, 339-49		32
1306	Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. <b>1993</b> , 48, 129-30		40
1305	Lack of variation in the nucleotide sequence corresponding to the transmembrane domain of the beta-amyloid precursor protein in Alzheimer's disease. <b>1993</b> , 48, 131-6		6
1304	Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro. <b>1993</b> , 34, 631-3		57
1303	Molecular genetics in neurology. <b>1993</b> , 34, 757-73		43
1302	Ubiquitinated neurites are associated with preamyloid and cerebral amyloid beta deposits in patients with hereditary cerebral hemorrhage with amyloidosis Dutch type. <b>1993</b> , 85, 267-71		12
1301	A physical map of the human APP gene in YACs. <b>1993</b> , 4, 662-9		8
1300	Adding to the amyloidoses. <i>Nature Genetics</i> , <b>1993</b> , 3, 185-6	36.3	2
1299	No linkage to chromosome 14 in Swedish Alzheimer's disease families. <i>Nature Genetics</i> , <b>1993</b> , 4, 218-9	36.3	20
1298	Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice [corrected]. <i>Nature Genetics</i> , <b>1993</b> , 5, 22-30	36.3	302
1297	Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. <b>1993</b> , 361, 260-3		515

1296	Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. <b>1993</b> , 91, 255-63	26
1295	No evidence for a point mutation at codon 713 and 717 of amyloid precursor protein gene in Japanese schizophrenics. <b>1993</b> , 38, 407-11	5
1294	Screening of amyloid precursor protein gene mutation (APP 717 Val-->Ile) in Swedish families with Alzheimer's disease. <b>1993</b> , 6, 151-6	4
1293	Genetic and molecular advances in Alzheimer's disease. <b>1993</b> , 16, 398-403	178
1292	Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. <b>1993</b> , 16, 403-9	384
1291	Alzheimer's disease: molecular genetics and transgenic animal models. <b>1993</b> , 57, 207-13	111
1290	Clinical studies in Alzheimer patients with positron emission tomography. <b>1993</b> , 57, 215-24	59
1289	Alzheimer's disease families with amyloid precursor protein mutations. <b>1993</b> , 695, 198-202	35
1288	Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. <b>1993</b> , 161, 17-20	86
1287	An introduction to the molecular genetics of neurological disease. Recent advances. <b>1993</b> , 50, 1123-8	7
1286	Molecular genetics of Alzheimer's disease. <b>1993</b> , 5, 417-25	9
1285	Chondroitin sulfate proteoglycan form of cellular and cell-surface Alzheimer amyloid precursor. <b>1993</b> , 154, 121-4	27
1284	A novel silent variant at codon 711 and a variant at codon 708 of the APP sequence detected in Spanish Alzheimer and control cases. <b>1993</b> , 150, 33-4	13
1283	Processing of the beta-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation. <b>1993</b> , 152, 185-9	31
1282	Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden. <b>1993</b> , 153, 85-7	15
1281	Screening for the APP codon 670/671 mutations in Alzheimer's disease. <b>1993</b> , 154, 161-2	5
1280	Purification and cloning of monkey proteases involved in the processing of the beta-amyloid precursor protein. <b>1993</b> , 14, 677-9	
1279	Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene. <b>1993</b> , 14, 407-19	85

1278	Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-protein. <b>1993</b> , 1158, 120-8	4
1277	Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. <b>1993</b> , 75, 1039-42	74 <sup>o</sup>
1276	Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer's disease. <b>1993</b> , 695, 103-8	28
1275	Sequencing of exons 16 and 17 of the beta-amyloid precursor protein gene fails to identify new mutations in Swedish Alzheimer's disease patients. <b>1993</b> , 2, 1045-6	8
1274	Molecular pathology of Alzheimer's disease. <b>1993</b> , 5, 351-362	6
1273	Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. <b>1993</b> , 259, 514-6	863
1272	Molecular pathology of Alzheimer's disease. <b>1993</b> , 56, 583-6	26
1271	Molecular genetics of Alzheimer's disease. <b>1993</b> , 50, 1164-72	77
1270	Cleavage of full-length beta APP mRNA by hammerhead ribozymes. <b>1993</b> , 21, 4119-25	35
1269	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. <b>1993</b> , 90, 9649-53	1288
1268	Chapter 6. Perspectives on Amyloid and Alzheimer's Disease: A Critical Review. <b>1993</b> , 28, 49-58	7
1267	High-level expression and in vitro mutagenesis of a fibrillogenic 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein. <b>1993</b> , 294 ( Pt 3), 667-74	10
1266	Patent Evaluation: A genetic marker for Alzheimer's disease. <b>1993</b> , 3, 1673-1675	
1265	Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. <b>1993</b> , 90, 9195-8	261
1264	Expression and processing of pathologic proteins in alzheimer's disease. <b>1993</b> , 3, 227-237	13
1263	The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. <b>1993</b> , 293 ( Pt 1), 27-30	274
1262	Alzheimer's disease and chromosome 14. Different gene, same process?. <b>1993</b> , 163, 2-5	9
1261	Expression of the human beta-amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice. <b>1993</b> , 90, 10578-82	84

1260	Genetics of Alzheimer's disease. Some molecular understanding of a diverse phenotype. <b>1994</b> , 164, 153-6	3
1259	Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein. <b>1994</b> , 14, 3122-38	151
1258	Alzheimer's Disease: Clinical Molecular Genetics. <b>1994</b> , 10, 239-247	14
1257	A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation. <b>1994</b> , 51, 1193-7	51
1256	Processing of Alzheimer A beta-amyloid precursor protein: cell biology, regulation, and role in Alzheimer disease. <b>1994</b> , 36, 29-50	42
1255	Characterization by radiosequencing of the carboxyl-terminal derivatives produced from normal and mutant amyloid $\beta$ protein precursors. <b>1994</b> , 1, 30-38	18
1254	A processing pathway for amyloid $\beta$ protein precursor generates a secreted form with an intact carboxyl terminus. <b>1994</b> , 1, 221-231	5
1253	An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. <b>1994</b> , 264, 1336-40	1377
1252	Alzheimer's disease, beta-amyloidosis, and aging. <b>1994</b> , 5, 275-92	23
1251	Alzheimer's disease: progress in pathological and aetiological aspects. <b>1994</b> , 4, 43-60	9
1250	Alzheimer's disease amyloid precursor protein (ApPP): proteolytic processing, secretases and A4 amyloid production. <b>1994</b> , 1, 263-280	40
1249	Mutational analysis of the amyloid precursor protein gene in Japanese familial Alzheimer's disease kindreds. <b>1994</b> , 93, 460-2	10
1248	Cadmium in blood in Alzheimer's disease and non-demented subjects: results from a population-based study. <b>1994</b> , 7, 130-4	25
1247	Amyloid precursor protein is enriched in radial glia: implications for neuronal development. <b>1994</b> , 37, 538-50	30
1246	Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. <b>1994</b> , 25, 439-50	145
1245	Immunocytochemical localization of amyloid precursor protein in rat brain. <b>1994</b> , 348, 244-60	32
1244	Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. <b>1994</b> , 11, 539-51	82
1243	Alzheimer's disease: Recent advances in molecular pathology and genetics. <b>1994</b> , 9, 431-444	7

1242	Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease. <b>1994</b> , 35, 432-8		25
1241	Are the associations between Alzheimer's disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium?. <b>1994</b> , 36, 97-100		79
1240	Decreased levels of soluble amyloid beta-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs. <b>1994</b> , 36, 215-20		14
1239	Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. <b>1994</b> , 36, 362-7		87
1238	Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. <b>1994</b> , 36, 903-11		101
1237	Unifying features of systemic and cerebral amyloidosis. <b>1994</b> , 8, 49-64		59
1236	The molecular genetics of Alzheimer's disease. <b>1994</b> , 9, 15-22		18
1235	The role of beta-amyloid peptide in Alzheimer's disease. <b>1994</b> , 9, 3-31		6
1234	Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation. <i>Nature Genetics</i> , <b>1994</b> , 6, 251-5	36.3	91
1233	Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. <i>Nature Genetics</i> , <b>1994</b> , 7, 74-8	36.3	413
1232	Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?. <b>1994</b> , 20, 322-38		21
1231	Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation. <b>1994</b> , 224, 265-71		53
1230	Alzheimer's disease: a molecular perspective. <b>1994</b> , 235, 195-8		2
1229	Endogenous neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy. <b>1994</b> , 11, 3-33		281
1228	Developmental changes of sialylation of soluble beta/A4 amyloid protein precursor derivatives in human cerebrospinal fluid. <b>1994</b> , 27, 320-2		
1227	Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. <b>1994</b> , 26, 207-17		70
1226	Oxygen-free radicals and amyloidosis in Alzheimer's disease: is there a connection?. <b>1994</b> , 15, 457-9; discussion 473		8
1225	Author's response to commentaries. <b>1994</b> , 15, 473		1

1224	APP processing, A beta-amyloidogenesis, and the pathogenesis of Alzheimer's disease. <b>1994</b> , 15, 253-6	37
1223	Future directions for research on Alzheimer's disease. <b>1994</b> , 15 Suppl 2, S117-9	121
1222	Cellular and molecular genetic approaches in Alzheimer's disease. <b>1994</b> , 15 Suppl 2, S135-7	2
1221	Genetic studies of Alzheimer's disease: lessons learned and future imperatives. <b>1994</b> , 15 Suppl 2, S145-8	2
1220	Genes in early onset Alzheimer's disease: implications for AD research. <b>1994</b> , 15 Suppl 2, S149-53	4
1219	Targets for Alzheimer's disease research: from basic mechanisms to rational therapies. <b>1994</b> , 15 Suppl 2, S157-60	
1218	The future of Alzheimer's disease research: a molecular genetic perspective. <b>1994</b> , 15 Suppl 2, S161-4	22
1217	Complex genetic disease: can genetic strategies in Alzheimer's disease and new genetic mechanisms be applied to epilepsy?. <b>1994</b> , 35 Suppl 1, S20-8	4
1216	Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). <b>1994</b> , 13, 45-53	1509
1215	Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate. <b>1994</b> , 174, 173-6	26
1214	Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. <b>1994</b> , 47, 1275-84	96
1213	Increased beta-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation. <b>1994</b> , 354, 274-8	101
1212	Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. <b>1994</b> , 168, 254-6	71
1211	Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the beta-amyloid precursor protein. <b>1994</b> , 60, 607-19	46
1210	Cellular and molecular biology of Alzheimer's disease and animal models. <b>1994</b> , 45, 435-46	112
1209	The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis. <b>1994</b> , 25, 73-80	19
1208	Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. <b>1994</b> , 4, 708-16	89
1207	Absence of APP713 mutation in Italian and Russian families with schizophrenia. <b>1994</b> , 165, 45-7	4

1206	Lack of association between apolipoprotein E allele epsilon 4 and sporadic Alzheimer's disease. <b>1994</b> , 169, 175-8	53
1205	Identification of full length $\beta$ amyloid precursor protein in human neuronal and non-neuronal cell culture supernatant: a possible extracellular source for the generation of A $\beta$ <b>1994</b> , 1, 232-239	4
1204	Identification of a metalloprotease from Alzheimer's disease brain able to degrade the beta-amyloid precursor protein and generate amyloidogenic fragments. <b>1994</b> , 33, 192-9	52
1203	Calcium ionophore increases amyloid beta peptide production by cultured cells. <b>1994</b> , 33, 4550-61	212
1202	Amyloidosis in Alzheimer's disease. <b>1994</b> , 22, 171-5	3
1201	Amyloid precursor protein gene mutation at codon 670/671 in familial Alzheimer's disease in Sweden. <b>1994</b> , 22, 176-9	3
1200	Advanced glycation end products contribute to amyloidosis in Alzheimer disease. <b>1994</b> , 91, 4766-70	682
1199	Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. <b>1994</b> , 91, 11993-7	283
1198	Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. <b>1994</b> , 91, 8378-82	372
1197	Genetic dissection of Alzheimer disease, a heterogeneous disorder. <b>1995</b> , 92, 8552-9	157
1196	Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. <b>1995</b> , 118 ( Pt 1), 185-205	81
1195	The toxicity in vitro of beta-amyloid protein. <b>1995</b> , 311 ( Pt 1), 1-16	430
1194	Human Nervous System. <b>1995</b> , 325-344	3
1193	Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S. <b>1995</b> , 311 ( Pt 1), 299-305	77
1192	Heat shock protein 70 mRNA levels in mononuclear blood cells from patients with dementia of the Alzheimer type. <b>1995</b> , 6, 301-5	2
1191	[18] Proteolytic processing of amyloid protein precursor of Alzheimer's disease. <b>1995</b> , 23, 317-327	1
1190	Basolateral secretion of amyloid precursor protein in Madin-Darby canine kidney cells is disturbed by alterations of intracellular pH and by introducing a mutation associated with familial Alzheimer's disease. <b>1995</b> , 270, 4058-65	59
1189	Early onset Alzheimer's disease in a South American pedigree from Argentina. <b>1995</b> , 91, 6-13	7



1188	Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. <b>1995</b> , 60, 1-6	63
1187	Clinical features of early onset, familial Alzheimer's disease linked to chromosome 14. <b>1995</b> , 60, 44-52	7
1186	Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease. <b>1995</b> , 60, 456-60	31
1185	Evidence for apolipoprotein E epsilon 4 association in early-onset Alzheimer's patients with late-onset relatives. <b>1995</b> , 60, 550-3	23
1184	Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. <b>1995</b> , 38, 254-9	378
1183	Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy. <b>1995</b> , 38, 267-9	14
1182	The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. <b>1995</b> , 38, 653-8	35
1181	Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. <b>1995</b> , 38, 797-808	65
1180	Characterization of the high affinity heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II). <b>1995</b> , 8, 247-57	40
1179	The neurobiology and genetics of Alzheimer's disease. <b>1995</b> , 10, S243-S246	3
1178	Aluminium and the risk for alzheimer's disease. <b>1995</b> , 6, 233-275	164
1177	Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. <b>1995</b> , 12, 83-92	56
1176	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. <b>1995</b> , 25, 149-59	76
1175	Characterization of muscarinic acetylcholine receptors in cultured adult skin fibroblasts: effects of the Swedish Alzheimer's disease APP 670/671 mutation on binding levels. <b>1995</b> , 10, 1-10	10
1174	Linkage and haplotype analysis of familial early-onset Alzheimer disease in Japanese population. <b>1995</b> , 40, 229-41	6
1173	The metabolism of the amyloid precursor protein and its relevance to Alzheimer's disease. <b>1995</b> , 2, 363-369	1
1172	A mouse model for Down syndrome exhibits learning and behaviour deficits. <i>Nature Genetics</i> , <b>1995</b> , 11, 177-84	36.3 739
1171	Sand in the sheets. <b>1995</b> , 1, 120-2	7

1170	Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. <b>1995</b> , 1, 829-32	151
1169	A potential role for apoptosis in neurodegeneration and Alzheimer's disease. <b>1995</b> , 10, 19-45	340
1168	Calretinin-immunoreactive neurons are resistant to beta-amyloid toxicity in vitro. <b>1995</b> , 671, 293-8	46
1167	Amyloid, aluminium and the aetiology of Alzheimer's disease. <b>1995</b> , 163, 256-9	26
1166	Monthly Update: Central & Peripheral Nervous Systems: Mutations in the S182 gene cause Alzheimer's disease - another therapeutic opportunity?. <b>1995</b> , 4, 871-874	
1165	Molecular Genetic Advances in Neurodegenerative Disorders. <b>1995</b> , 15, 915-926	2
1164	The genetics of Alzheimer's disease and mutations in the amyloid Eprotein precursor gene. <b>1995</b> , 59-78	5
1163	Role of the beta-amyloid protein in Alzheimer's disease. <b>1995</b> , 9, 366-70	237
1162	Accumulation of aluminium and silicon in lipofuscin granules. <b>1995</b> , 41 Suppl 2, 131-44	12
1161	Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. <b>1995</b> , 15, 4896-905	49
1160	Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence.. <b>1995</b> , 14, 4932-4938	137
1159	Alzheimer's disease—ew approaches to old problems. <b>1995</b> , 7, 419-435	1
1158	The COOH-terminus of the Alzheimer amyloid A $\beta$ peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-associated amyloid deposits. <b>1995</b> , 2, 195-203	13
1157	The chondroitin sulfate attachment site of appican is formed by splicing out exon 15 of the amyloid precursor gene. <b>1995</b> , 270, 10388-91	42
1156	The Ras-related GTP-binding protein, Rab1B, regulates early steps in exocytic transport and processing of beta-amyloid precursor protein. <b>1995</b> , 270, 10982-9	51
1155	Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. <b>1995</b> , 270, 26727-30	67
1154	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. <b>1995</b> , 7, 361-383	2
1153	Immunohistochemical analysis of COOH-termini of amyloid beta protein (A $\beta$ ) using end-specific antisera for A $\beta$ 0 and A $\beta$ 2 in Alzheimer's disease and normal aging. <b>1995</b> , 2, 7-16	21

1152	Nucleotide sequence of the chromosome 14-encoded S182 cDNA and revised secondary structure prediction. <b>1995</b> , 2, 188-190	14
1151	Polarized sorting of beta-amyloid precursor protein and its proteolytic products in MDCK cells is regulated by two independent signals. <b>1995</b> , 128, 537-47	124
1150	Cell-type and amyloid precursor protein-type specific inhibition of A beta release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. <b>1995</b> , 270, 2419-22	93
1149	The Amyloid Peptide and Its Precursor in Alzheimer's Disease. <b>1995</b> , 6,	23
1148	Altered expression of transforming growth factor-beta in Alzheimer's disease. <b>1995</b> , 45, 1561-9	138
1147	Transgenic mice and modeling Alzheimer's disease. <b>1995</b> , 6, 87-96	6
1146	No evidence that common allelic variation in the Amyloid Precursor Protein (APP) gene confers susceptibility to Alzheimer's disease. <b>1995</b> , 4, 853-8	20
1145	The vacuolar H(+)-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type beta-amyloid precursor protein. <b>1995</b> , 270, 6186-92	79
1144	The prevention of neurogenetic disease. <b>1995</b> , 52, 356-62	8
1143	Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. <b>1995</b> , 4, 2373-7	227
1142	Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. <b>1995</b> , 270, 18666-71	142
1141	Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. <b>1995</b> , 15, 1203-18	482
1140	Generation of amyloid beta protein from its precursor is sequence specific. <b>1995</b> , 14, 661-70	263
1139	YAC transgenics and the study of genetics and human disease. <b>1995</b> , 5, 342-8	40
1138	Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. <b>1995</b> , 201, 45-7	35
1137	A mutation in codon 717 of the amyloid precursor protein gene in an Australian family with Alzheimer's disease. <b>1995</b> , 199, 183-6	32
1136	Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. <b>1995</b> , 199, 203-6	34
1135	The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. <b>1995</b> , 26, 254-7	78

1134	Alzheimer's disease: maladaptive synaptotoxicity hypothesis. <b>1995</b> , 4, 217-32	24
1133	Two-dimensional gel mapping of the processing of the human amyloid precursor protein in rat hippocampal neurons. <b>1995</b> , 368, 363-6	11
1132	Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family. <b>1995</b> , 28, 319-37	58
1131	Mutant and native human beta-amyloid precursor proteins in transgenic mouse brain. <b>1995</b> , 16, 685-99	42
1130	New hopes arise with the transgenic model for Alzheimer's disease. <b>1995</b> , 16, 701-3	1
1129	The potential utility of transgenic mice harboring beta-amyloid precursor protein. <b>1995</b> , 16, 711-3; discussion 715-8	3
1128	Expression of the amyloid protein precursor of Alzheimer's disease in the developing rat olfactory system. <b>1995</b> , 88, 87-95	43
1127	The identification of an Alzheimer's disease gene on chromosome 14 opens new avenues for research. The views of an amyloidologist. <b>1995</b> , 2, 213-216	
1126	The role of beta-amyloid in the development of Alzheimer's disease. <b>1995</b> , 7, 97-109	11
1125	A mitochondrial bottleneck hypothesis of Alzheimer's disease. <b>1995</b> , 1, 240-7	15
1124	Amyloid precursor protein mutation at codon 713 (Ala-->Val) does not cause schizophrenia: non-pathogenic variant found at codon 705 (silent). <b>1995</b> , 184, 90-3	19
1123	Héřogéht'géhéřique de la maladie d'Alzheimer. <b>1996</b> , 7, 27-30	
1122	Artifactual strain-specific signs of incipient brain amyloidosis in APP transgenic mice. <b>1996</b> , 17, 223-34	9
1121	Expression of APP in transgenic mice: a comparison of neuron-specific promoters. <b>1996</b> , 17, 183-90	78
1120	Lack of beta-amyloidosis in transgenic mice expressing low levels of familial Alzheimer's disease missense mutations. <b>1996</b> , 17, 205-14	22
1119	Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent. <b>1996</b> , 17, 173-82	25
1118	APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. <b>1996</b> , 17, 153-71	44
1117	Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. <b>1996</b> , 17, 773-80	98

1116	Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. <b>1996</b> , 802, 42-9	8
1115	Clinical and neuroimaging features of familial Alzheimer's disease. <b>1996</b> , 777, 49-56	23
1114	Screening for amyloid beta precursor protein codon 665, 670/671 and 717 mutations in Finnish patients with Alzheimer's disease. <b>1996</b> , 205, 68-70	
1113	Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. <b>1996</b> , 214, 163-6	62
1112	Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients. <b>1996</b> , 59, 477-89	48
1111	Baculovirus-infected cells do not produce the amyloid peptide of Alzheimer's disease from its precursor. <b>1996</b> , 389, 157-61	7
1110	The gene defects responsible for familial Alzheimer's disease. <b>1996</b> , 3, 159-68	246
1109	Missense mutations associated with familial Alzheimer's disease in Sweden lead to the production of the amyloid peptide without internalization of its precursor. <b>1996</b> , 218, 89-96	20
1108	Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. <b>1996</b> , 2, 864-70	2305
1107	Clinical features of sporadic and familial Alzheimer's disease. <b>1996</b> , 5, 393-7	24
1106	Inhibition of amyloid beta-protein production in neural cells by the serine protease inhibitor AEBSE. <b>1996</b> , 17, 171-9	86
1105	Alzheimer-associated presenilin-2 confers increased sensitivity to apoptosis in PC12 cells. <b>1996</b> , 397, 50-4	105
1104	Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation. <b>1996</b> , 220, 9-12	31
1103	Molecular genetics of Alzheimer's disease. <b>1996</b> , 165, 13-7	20
1102	Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). <b>1996</b> , 165, 72-84	14
1101	Biological markers and diagnostic investigations in Alzheimer's disease. <b>1996</b> , 165, 85-91	4
1100	Intracellular generation of amyloid beta-protein from amyloid beta-protein precursor fragment by direct cleavage with beta- and gamma-secretase. <b>1996</b> , 218, 238-42	33
1099	Transgenic models of neurodegenerative diseases. <b>1996</b> , 6, 651-60	26

1098	Mechanisms of neuronal degeneration in Alzheimer's disease. <b>1996</b> , 16, 921-32	897
1097	Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. <b>1996</b> , 17, 1005-13	1350
1096	Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. <b>1996</b> , 17, 181-90	999
1095	The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). <b>1996</b> , 271, 1406-9	618
1094	Progress in Molecular Genetics of Alzheimer's Disease. <b>1996</b> , 2, 3-6	5
1093	Alzheimer's syndrome, not Alzheimer's disease. <b>1996</b> , 44, 96-7	3
1092	Biological markers for the clinical diagnosis of Alzheimer's disease. <b>1996</b> , 179, 65-79	19
1091	Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. <b>1996</b> , 93, 2065-70	52
1090	Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. <b>1996</b> , 46, 413-9	133
1089	Alzheimer's disease amyloid precursor protein on the surface of cortical neurons in primary culture co-localizes with adhesion patch components. <b>1996</b> , 735, 217-31	69
1088	Early-onset dementias: clinical, neuropathological and genetic characteristics. <b>1996</b> , 91, 451-65	19
1087	Plaque formation in brain transplants exposed to human beta-amyloid precursor protein 695. <b>1996</b> , 92, 130-7	15
1086	The heat shock/oxidative stress connection. Relevance to Alzheimer disease. <b>1996</b> , 28, 21-34	30
1085	The molecular significance of amyloid beta-peptide for Alzheimer's disease. <b>1996</b> , 246, 118-23	18
1084	A beta A4 amyloid precursor protein gene and Alzheimer's disease. <b>1996</b> , 237, 6-15	30
1083	Genetics of Alzheimer's disease. <b>1996</b> , 168, 25-7	2
1082	Application of PET in dementia disorders. <b>1996</b> , 168, 71-6	31
1081	Pharmacological treatment of cognitive dysfunction in dementia disorders. <b>1996</b> , 168, 87-92	22

1080	A vector for expressing foreign genes in the brains and hearts of transgenic mice. <b>1996</b> , 13, 159-63	290
1079	Genetic factors in Alzheimer's disease: a review of recent advances. <b>1996</b> , 40, 829-40	68
1078	Editorial Review. The genetics of Alzheimer's disease—new opportunities and new challenges. <b>1996</b> , 11, 491-497	6
1077	Metabolites of the beta-amyloid precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells. <b>1996</b> , 46, 211-25	34
1076	Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. <b>1996</b> , 46, 283-93	30
1075	The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. <b>1996</b> , 271, 28655-9	135
1074	Beta-amyloid precursor protein. Location of transmembrane domain and specificity of gamma-secretase cleavage. <b>1996</b> , 271, 21914-9	69
1073	cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. <b>1996</b> , 5, 1589-98	95
1072	Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. <b>1996</b> , 5, 985-8	198
1071	No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. <b>1996</b> , 33, 661-4	14
1070	Amyloid beta peptide formation in cell-free preparations. Regulation by protein kinase C, calmodulin, and calcineurin. <b>1996</b> , 271, 24670-4	41
1069	Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. <b>1996</b> , 271, 27241-4	73
1068	Japanese siblings with missense mutation (717Val --> Ile) in amyloid precursor protein of early-onset Alzheimer's disease. <b>1996</b> , 46, 1721-3	16
1067	Amyloid beta-protein and the genetics of Alzheimer's disease. <b>1996</b> , 271, 18295-8	654
1066	Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. <b>1996</b> , 271, 23380-8	113
1065	Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. <b>1996</b> , 271, 8966-70	135
1064	Protein folding, nucleation phenomena and delayed neurodegeneration in Alzheimer's disease. <b>1996</b> , 7, 21-8	8
1063	The Genes Involved in Alzheimer's Disease. <b>1996</b> , 49-59	

1062	Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-amyloid precursor protein occurs in both secretory and endocytic pathways. <b>1996</b> , 271, 9100-7	100
1061	The A4 amyloid precursor protein gene and Alzheimer's disease. <b>1996</b> , 89-98	
1060	[Risk factors in Alzheimer's dementia]. <b>1996</b> , 64, 425-32	15
1059	A beta amyloidogenesis: unique, or variation on a systemic theme?. <b>1997</b> , 32, 361-404	69
1058	Molecular neurobiology of Alzheimer's disease (syndrome?). <b>1997</b> , 5, 177-213	26
1057	Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. <b>1997</b> , 272, 7977-82	236
1056	Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. <b>1997</b> , 6, 1951-9	140
1055	The role of amyloid in the pathogenesis of Alzheimer's disease. <b>1997</b> , 378, 937-50	33
1054	Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. <b>1997</b> , 272, 1896-903	55
1053	Apoptosis, neurotrophic factors and neurodegeneration. <b>1997</b> , 8, 223-65	38
1052	Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. <b>1997</b> , 6, 1535-41	90
1051	Controlling amyloid beta-peptide fibril formation with protease-stable ligands. <b>1997</b> , 272, 12601-5	183
1050	Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. <b>1997</b> , 272, 22987-90	254
1049	Differential effects of the swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells. <b>1997</b> , 272, 32247-53	47
1048	Classification of amyloid fibril proteins and their precursors: An ongoing discussion. <b>1997</b> , 4, 216-218	19
1047	Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. <b>1997</b> , 54, 641-4	71
1046	Evidence for phosphorylation and oligomeric assembly of presenilin 1. <b>1997</b> , 94, 5090-4	151
1045	Membrane protein secretases. <b>1997</b> , 321 ( Pt 2), 265-79	573



1044	Genetic epidemiology of Alzheimer disease. <b>1997</b> , 19, 107-19	35
1043	Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. <b>1997</b> , 9 Suppl 1, 11-38	23
1042	Differential regulation of adenylyl cyclase in fibroblasts from sporadic and familial Alzheimer's disease cases with PS1 and APP mutations. <b>1997</b> , 8, 2031-5	14
1041	Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. <b>1997</b> , 94, 13287-92	1213
1040	The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. <b>1997</b> , 94, 2025-30	351
1039	Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. <b>1997</b> , 94, 1550-5	585
1038	Interactions of the Alzheimer beta amyloid fragment (25-35) with peripheral blood dendritic cells. <b>1997</b> , 94, 223-32	21
1037	Reactive oxygen species and Alzheimer's disease. <b>1997</b> , 54, 533-9	199
1036	APP gene promoter constructs are preferentially expressed in the CNS and testis of transgenic mice. <b>1997</b> , 240, 759-62	21
1035	Amyloid precursor protein, copper and Alzheimer's disease. <b>1997</b> , 51, 105-11	39
1034	Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. <b>1997</b> , 19, 939-45	885
1033	The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. <b>1997</b> , 402, 95-8	150
1032	Alzheimer's alpha-secretase may be a calcium-dependent protease. <b>1997</b> , 417, 163-7	16
1031	Proteolytical processing of mutated human amyloid precursor protein in transgenic mice. <b>1997</b> , 47, 108-16	30
1030	Abnormalities in Alzheimer's disease fibroblasts bearing the APP670/671 mutation. <b>1997</b> , 18, 573-80	45
1029	Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. <b>1997</b> , 18, 591-608	82
1028	Lack of effect of Presenilin 1, APP and their Alzheimer's disease-related mutated forms on Xenopus oocytes membrane currents. <b>1997</b> , 221, 85-88	5
1027	Conserved elements in the 5' regulatory region of the amyloid precursor protein gene in primates. <b>1997</b> , 226, 203-6	10

1026	Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene. <b>1997</b> , 228, 17-20	45
1025	Mutation analysis of chromosome 19 calmodulin (CALM3) gene in Alzheimer's disease patients. <b>1997</b> , 229, 157-60	3
1024	A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease. <b>1997</b> , 234, 3-6	30
1023	Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. <b>1997</b> , 17, 7053-9	448
1022	Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. <b>1997</b> , 94, 4125-30	144
1021	Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid $\beta$ Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases. <b>1997</b> , 3, 695-707	137
1020	Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. <b>1997</b> , 8, 288-95	11
1019	Examination of the role of endopeptidase 3.4.24.15 in A beta secretion by human transfected cells. <b>1997</b> , 121, 556-62	34
1018	Chlorpromazine reduces toxicity and Ca <sup>2+</sup> uptake induced by amyloid beta protein (25-35) in vitro. <b>1997</b> , 748, 184-8	20
1017	Cathepsin D displays in vitro beta-secretase-like specificity. <b>1997</b> , 750, 11-9	88
1016	Lysosomal generation of amyloid beta protein species in transgenic mice. <b>1997</b> , 765, 343-8	5
1015	Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. <b>1997</b> , 22, 49-56	148
1014	Metallothioneins in brain--the role in physiology and pathology. <b>1997</b> , 142, 229-42	164
1013	In vitro neurotoxicity of amyloid $\beta$ peptide cross-linked by transglutaminase. <b>1997</b> , 23, 77-85	5
1012	Effects of acidosis on the distribution of processing of the beta-amyloid precursor protein in cultured hippocampal neurons. <b>1997</b> , 31, 171-86	27
1011	The genetics and pathophysiology of Alzheimer's disease. <b>1997</b> , 242, 281-4	3
1010	Butyrylcholinesterase in the life cycle of amyloid plaques. <b>1997</b> , 42, 909-18	241
1009	Defective neurite extension is caused by a mutation in amyloid $\beta$ A4 (A $\beta$ ) protein precursor found in Familial Alzheimer's Disease. <b>1997</b> , 32, 469-480	46

1008	E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. <b>1997</b> , 10, 186-95	59
1007	Rapid impact of beta-amyloid on paxillin in a neural cell line. <b>1997</b> , 50, 979-89	19
1006	Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis. <b>1998</b> , 8, 735-57	20
1005	The implications of genetic studies on the pathogenesis of Alzheimer's disease. <b>1998</b> , 18, 103-110	
1004	Alzheimer's disease as a polygenic disease. <b>1998</b> , 18, 111-115	1
1003	Modelling motor neuron degenerative disease. <b>1998</b> , 24, 90-6	2
1002	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). <b>1998</b> , 6, 176-80	10
1001	A beta peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis. <b>1998</b> , 3, 284-6, 282-3	6
1000	The role of A beta 42 in Alzheimer's disease. <b>1998</b> , 92, 289-92	213
999	Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein. <b>1998</b> , 12, 172-8	5
998	Initial results of a genome survey for novel Alzheimer's disease risk genes: association with a locus on the X chromosome. <b>1998</b> , 81, 98-107	11
997	Initial results of a genome survey for novel Alzheimer's disease risk genes: Association with a locus on the X chromosome. <b>1998</b> , 81, 196-205	19
996	A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease. <b>1998</b> , 1, 293-6	33
995	Monogenetic determinants of Alzheimer's disease: APP mutations. <b>1998</b> , 54, 897-901	28
994	Phenotype analysis in neurological models of human disease. <b>1998</b> , 24, 83-87	2
993	Myelin disorders. <b>1998</b> , 24, 87-90	3
992	Genetic modelling of muscular dystrophies. <b>1998</b> , 24, 96-100	2
991	Transgenic models for Alzheimer's disease. <b>1998</b> , 24, 101-3	12

990	Phenotype analysis in neurological models of human disease. <b>1998</b> , 24, 83-7	4
989	Myelin disorders. <b>1998</b> , 24, 87-90	2
988	Introduction. <b>1998</b> , 24, 82-82	1
987	Transgenic mice expressing an alpha-secretion mutant of the amyloid precursor protein in the brain develop a progressive CNS disorder. <b>1998</b> , 95, 55-64	19
986	Biochemical diagnostic markers to detect early Alzheimer's disease. <b>1998</b> , 19, 165-7	7
985	Role of genetics in tests of genotype, status, and disease progression in early-onset Alzheimer's disease. <b>1998</b> , 19, 133-7	21
984	Accumulation of amyloid beta protein in transgenic mice. <b>1998</b> , 19, S59-63	7
983	An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. <b>1998</b> , 20, 603-9	128
982	Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Abeta1-42/43 expression. <b>1998</b> , 20, 611-7	169
981	Alzheimer's disease: genetic studies and transgenic models. <b>1998</b> , 32, 461-93	349
980	Alzheimer's disease: identification of genes and genetic risk factors. <b>1998</b> , 117, 315-25	7
979	Mutant genes in familial Alzheimer's disease and transgenic models. <b>1998</b> , 21, 479-505	516
978	Potential therapeutic targets for Alzheimer's disease. <b>1998</b> , 2, 157-179	5
977	The neurotoxicity of amyloid beta protein in aged primates. <b>1998</b> , 5, 1-9	49
976	Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer's disease brains. <b>1998</b> , 12, 55-65	8
975	A genome survey for novel Alzheimer disease risk loci: results at 10-cM resolution. <b>1998</b> , 50, 121-8	91
974	Flemish and Dutch mutations in amyloid beta precursor protein have different effects on amyloid beta secretion. <b>1998</b> , 5, 281-6	138
973	An overview of Alzheimer's disease research. <b>1998</b> , 104, 26S-31S; discussion 39S-42S	8

972	Treatment of Alzheimer's disease: current approaches and promising developments. <b>1998</b> , 104, 32S-38S; discussion 39S-42S	27
971	Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. <b>1998</b> , 7, 933-5	32
970	Recent advances in the genetics of Alzheimer's disease. <b>1998</b> , 11, 42-54	35
969	X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. <b>1998</b> , 273, 22351-7	122
968	Amyloid precursor protein processing in sterol regulatory element-binding protein site 2 protease-deficient Chinese hamster ovary cells. <b>1998</b> , 273, 15309-12	13
967	Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. <b>1998</b> , 95, 13703-8	128
966	The long term adenoviral expression of the human amyloid precursor protein shows different secretase activities in rat cortical neurons and astrocytes. <b>1998</b> , 273, 28931-6	27
965	Alzheimer's Syndrome and not Alzheimer's disease: The historical struggle to define the disease. <b>1998</b> , 13, 92-95	1
964	Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. <b>1998</b> , 55, 698-702	37
963	Molecular Genetics of Familial Alzheimer Disease. <b>1998</b> , 315, 266-272	
962	Genetic risk factors in Alzheimer's disease. <b>1998</b> , 51, 293-304	35
961	Introduction of hereditary disease-associated mutations into the beta-amyloid precursor protein gene of mouse embryonic stem cells: a comparison of homologous recombination methods. <b>1998</b> , 18, 4651-8	9
960	Alzheimer disease. <b>1998</b> , 42, 1-54	166
959	Epidemiologic and genetic studies of dementia of the alzheimer type in japan. <b>1998</b> , 9, 294-8	23
958	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. <b>1998</b> , 3, d436-46	18
957	Is understanding the biological function of APP important in understanding Alzheimer's disease?. <b>1999</b> , 1, 287-95	4
956	Apolipoprotein E and alpha1-antichymotrypsin genotypes and age of onset of familial Alzheimer's disease. <b>1999</b> , 10, 1-5	5
955	The genetics of Alzheimer's disease. <b>2000</b> , 32, 23-43	5

954	AB-induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes. <b>2000</b> , 32, 101-12	2
953	B-secretase : Tissue Culture Studies of Sequence Specificity, Inhibitors, and Candidate Enzymes. <b>2000</b> , 32, 229-38	
952	Designing Animal Models of Alzheimer's Disease with Amyloid Precursor Protein (APP) Transgenes. <b>2000</b> , 32, 249-70	
951	Molecular genetics of Alzheimer disease. <b>1999</b> , 19, 371-83	42
950	Development of Neopeptide Antibodies Against the B-secretase Cleavage Site in the Amyloid Precursor Protein. <b>2000</b> , 32, 217-28	
949	Cellular mechanisms of beta-amyloid production and secretion. <b>1999</b> , 96, 11049-53	402
948	Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. <b>1999</b> , 96, 4119-24	173
947	Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. <b>1999</b> , 10, 446-51	70
946	Hereditary cerebral hemorrhage with amyloidosis--Dutch type (HCHWA-D): a review of the variety in phenotypic expression. <b>1999</b> , 6, 215-24	26
945	Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. <b>1999</b> , 274, 6483-92	538
944	Rank-order of potencies for inhibition of the secretion of abeta40 and abeta42 suggests that both are generated by a single gamma-secretase. <b>1999</b> , 274, 20499-504	40
943	The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. <b>1999</b> , 122 ( Pt 9), 1709-19	99
942	Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. <b>1999</b> , 274, 26810-4	43
941	Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. <b>1999</b> , 6, 53-62	134
940	Regulation of amyloid precursor protein cleavage. <b>1999</b> , 72, 443-60	170
939	The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. <b>1999</b> , 25, 81-97	129
938	Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. <b>1999</b> , 2, 271-6	789
937	Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. <b>1999</b> , 1, 479-85	463

936	Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. <b>1999</b> , 402, 533-7	1319
935	Purification and cloning of amyloid precursor protein beta-secretase from human brain. <b>1999</b> , 402, 537-40	1464
934	Axon routing across the midline controlled by the Drosophila Derailed receptor. <b>1999</b> , 402, 540-4	114
933	Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. <b>1999</b> , 286, 735-41	3233
932	Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches. <b>1999</b> , 77, 412-8	60
931	[Inheritable causes and risk factors of Alzheimer's disease]. <b>1999</b> , 70, 195-205	12
930	Transfected human B cells: a new model to study the functional and immunostimulatory consequences of APP production. <b>1999</b> , 34, 783-95	15
929	Alzheimer's Disease. <b>1999</b> ,	
928	Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. <b>1999</b> , 96, 3228-33	972
927	Protein kinase C and amyloid precursor protein processing in skin fibroblasts from sporadic and familial Alzheimer's disease cases. <b>1999</b> , 1453, 341-50	19
926	Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. <b>1999</b> , 103, 145-62	183
925	Discussion. <b>1999</b> , 20, 85	18
924	Primate-like amyloid-beta sequence but no cerebral amyloidosis in aged tree shrews. <b>1999</b> , 20, 47-51	41
923	Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. <b>1999</b> , 20, 581-9	273
922	Clinical and neurobiological correlates of D10S1423 genotype in Alzheimer's disease. <b>1999</b> , 46, 740-9	11
921	Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. <b>1999</b> , 274, 25945-52	871
920	Cellular cofactors for amyloid beta-peptide-induced cell stress. Moving from cell culture to in vivo. <b>1999</b> , 155, 1403-11	28
919	Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. <b>1999</b> , 155, 1741-7	59

918	A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. <b>1999</b> , 10, 526-33	27
917	CHAPTER 5.6 Identification and functional analysis of genes and genetic risk factors in Alzheimer's disease. <b>1999</b> , 841-862	
916	Chapter 5.7 Aging, Alzheimer's disease and frameshift mutations. <b>1999</b> , 863-879	1
915	Early-onset Alzheimer's disease caused by a novel mutation at codon 219 of the presenilin-1 gene. <b>1999</b> , 10, 503-7	18
914	Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. <b>1999</b> , 156, 50-7	25
913	Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease. <b>1999</b> , 1, 275-85	50
912	Chapter 5.8 Transgenic mouse models of Alzheimer's disease. <b>1999</b> , 880-894	1
911	Genetic and biochemical markers for Alzheimer's disease: recent developments. <b>2000</b> , 37 ( Pt 5), 593-607	27
910	Neuronal death in Alzheimer's disease. <b>2000</b> , 39, 328-30	1
909	?????????????????????. <b>2000</b> , 74, 999-1003	
908	What transgenic mice tell us about neurodegenerative disease. <b>2000</b> , 22, 297-304	27
907	Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. <b>2000</b> , 88, 93-113	133
906	Presymptomatic Genetic Testing with an APP Mutation in Early-Onset Alzheimer Disease: A Descriptive Study of Sibship Dynamics. <b>2000</b> , 9, 327-41	4
905	Lewy body and Alzheimer pathology in a family with the amyloid-beta precursor protein APP717 gene mutation. <b>2000</b> , 100, 145-52	48
904	High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. <b>2000</b> , 20, 4050-8	1507
903	Amyloid-beta and treatment opportunities for Alzheimer's disease. <b>2000</b> , 2, 231-59	5
902	The genetics of the amyloidoses. <b>2000</b> , 51, 543-69	128
901	The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. <b>2000</b> , 54, 2045-54	126



900	Transgenic approaches to model Alzheimer's disease. <b>2000</b> , 11, 47-51	21
899	Isoaspartate formation and neurodegeneration in Alzheimer's disease. <b>2000</b> , 381, 225-34	154
898	Implication of novel biochemical property of beta-amyloid. <b>2000</b> , 267, 733-8	10
897	Overexpression of Rab11 or constitutively active Rab11 does not affect sAPPalpha and Abeta secretions by wild-type and Swedish mutated betaAPP-expressing HEK293 cells. <b>2000</b> , 275, 910-5	8
896	Overexpression of human amyloid precursor protein in Drosophila. <b>2000</b> , 4, 43-9	19
895	ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. <b>2000</b> , 16, 609-19	141
894	Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. <b>2000</b> , 7, 9-22	94
893	Molecular genetics of Alzheimer's disease. <b>2000</b> , 47, 183-99	249
892	Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein--initial observations. <b>2000</b> , 100, 259-86	68
891	Beta-secretase revealed: starting gate for race to novel therapies for Alzheimer's disease. <b>2000</b> , 21, 161-3	28
890	Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. <b>2000</b> , 60, 363-84	125
889	Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. <b>2000</b> , 9, 2589-98	112
888	Proteolytic activation of recombinant pro-memapsin 2 (pro-beta-secretase) studied with new fluorogenic substrates. <b>2000</b> , 39, 12450-6	114
887	A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta -secretase. <b>2000</b> , 275, 37712-7	210
886	Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. <b>2001</b> , 49, 200-10	273
885	Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. <b>2001</b> , 293, 1487-91	1253
884	Protein kinase C epsilon suppresses Abeta production and promotes activation of alpha-secretase. <b>2001</b> , 285, 997-1006	73
883	Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. <b>2001</b> , 8, 982-92	44

882	Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. <b>2001</b> , 158, 1173-7	232
881	beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. <b>2001</b> , 104, 299-310	61
880	Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. <b>2001</b> , 301, 54-8	38
879	The unfolded protein response and Alzheimer's disease. <b>2001</b> , 1536, 85-96	113
878	Gene identification in Alzheimer's disease. <b>2001</b> , 2, 239-49	21
877	The emerging utility of animal models of chronic neurodegenerative diseases. <b>2001</b> , 5, 125-32	5
876	Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. <b>2001</b> , 21, 9235-45	172
875	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. <b>2001</b> , 333-348	
874	Early-onset Alzheimer's disease in Scotland: environmental and familial factors. <b>2001</b> , 40, s53-9	14
873	Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. <b>2001</b> , 21, 372-81	870
872	Genetic markers in the diagnosis of Alzheimer's disease. <b>2001</b> , 3, 293-304	7
871	Characterization of recombinant, soluble beta-secretase from an insect cell expression system. <b>2001</b> , 59, 619-26	28
870	Distribution of a Human Brain Carboxypeptidase B Capable of Cleaving .BETA.-Amyloid Precursor Protein (APP) in Normal and Alzheimer's Diseased Brain.. <b>2001</b> , 34, 275-283	
869	Homozygosity and linkage disequilibrium mapping of autosomal recessive distal myopathy (Nonaka distal myopathy). <b>2001</b> , 46, 649-55	6
868	The beta-secretase, BACE: a prime drug target for Alzheimer's disease. <b>2001</b> , 17, 157-70	137
867	Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics. <b>2001</b> , 17, 233-57	11
866	Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization. <b>2001</b> , 17, 259-67	32
865	The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. <b>2001</b> , 4, 887-93	884

864	Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A. <b>2001</b> , 7, 381-391	2
863	Genes, models and Alzheimer's disease. <b>2001</b> , 17, 254-61	94
862	Apolipoprotein E deposition and astrogliosis are associated with maturation of beta-amyloid plaques in betaAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease. <b>2001</b> , 900, 48-56	32
861	Subcellular compartment and molecular subdomain of beta-amyloid precursor protein relevant to the Aβ <sub>42</sub> -promoting effects of Alzheimer mutant presenilin 2. <b>2001</b> , 276, 21678-85	47
860	BACE2 functions as an alternative alpha-secretase in cells. <b>2001</b> , 276, 34019-27	129
859	Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. <b>2001</b> , 276, 42027-34	80
858	The functions of the amyloid precursor protein gene. <b>2001</b> , 12, 1-39	28
857	Secretases as therapeutic targets for the treatment of Alzheimer's disease. <b>2001</b> , 8, 124-42	25
856	Retention of the Alzheimer's amyloid precursor fragment C99 in the endoplasmic reticulum prevents formation of amyloid beta-peptide. <b>2001</b> , 276, 20267-79	46
855	Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. <b>2001</b> , 276, 43446-54	139
854	The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase. <b>2001</b> , 276, 4476-84	55
853	Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Aβ <sub>42</sub> secretion and APP C-terminal fragment stability. <b>2001</b> , 10, 1665-71	145
852	The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. <b>2001</b> , 276, 10366-73	102
851	Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. <b>2002</b> , 277, 32046-53	1117
850	Explaining the cause of the amyloid burden in Alzheimer disease. <b>2002</b> , 59, 1367-8	11
849	The search for gamma-secretase and development of inhibitors. <b>2002</b> , 9, 1087-106	41
848	Genetically engineered models of neurodegenerative diseases. <b>2002</b> , 1841-1862	1
847	Alzheimer transgenic models. <b>2002</b> , 15, 433-439	1

846	The Arctic mutation interferes with processing of the amyloid precursor protein. <b>2002</b> , 13, 1857-60	40
845	Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. <b>2002</b> , 1, 5-20	45
844	Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. <b>2002</b> , 161, 507-20	92
843	Selective nicotinic receptor consequences in APP(SWE) transgenic mice. <b>2002</b> , 20, 354-65	58
842	Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. <b>2002</b> , 9, 61-8	164
841	The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. <b>2002</b> , 297, 353-6	10460
840	The role of beta-amyloid in Alzheimer's disease. <b>2002</b> , 86, 629-39	5
839	Disordered proteins in dementia. <b>2002</b> , 34, 259-71	17
838	Pharmacogenomics for the treatment of dementia. <b>2002</b> , 34, 357-79	39
837	Immunological approaches as therapy for Alzheimer's disease. <b>2002</b> , 2, 907-17	11
836	Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: new findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis. <b>2002</b> , 23, 225-30	22
835	Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. <b>2002</b> , 23, 1051-72	115
834	Biochemical and immunocytochemical characterization of calsenilin in mouse brain. <b>2002</b> , 114, 247-63	31
833	Confirmation of association between D10S583 and Alzheimer's disease in a case-control sample. <b>2002</b> , 325, 87-90	36
832	Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery. <b>2002</b> , 37, 31-40	1
831	Pharmacogenomics in Alzheimer's disease. <b>2002</b> , 2, 59-84	28
830	Biochemical investigations in patients with dementia. <b>2002</b> , 39, 211-20	0
829	Mutational spectral analysis at the HPRT locus in healthy children. <b>2002</b> , 505, 27-41	20

828	Amyloidosis and Alzheimer's disease. <b>2002</b> , 54, 1539-51	137
827	Beta-secretase (BACE) as a drug target for Alzheimer's disease. <b>2002</b> , 54, 1589-602	179
826	Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. <b>2002</b> , 956, 36-44	95
825	APOE polymorphism and clinical duration determine regional neuropathology in Swedish APP(670, 671) mutation carriers: implications for late-onset Alzheimer's disease. <b>2002</b> , 6, 199-214	20
824	Familial conformational diseases and dementias. <b>2002</b> , 20, 1-14	46
823	Preclinical experiments on cognition enhancement in Alzheimer's disease: Drugs affecting nicotinic acetylcholine receptors. <b>2002</b> , 56, 335-346	8
822	Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). <b>2002</b> , 81, 655-8	142
821	Pro-domain removal in ASP-2 and the cleavage of the amyloid precursor are influenced by pH. <b>2002</b> , 3, 25	19
820	Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. <b>1995</b> , 64, 307-15	69
819	Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. <b>1995</b> , 64, 2087-96	107
818	Apoptotic cell death induced by beta-amyloid 1-42 peptide is cell type dependent. <b>1995</b> , 65, 292-300	172
817	Expression of the chondroitin sulfate proteoglycans of amyloid precursor (appican) and amyloid precursor-like protein 2. <b>1995</b> , 65, 762-9	30
816	Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. <b>1996</b> , 66, 2300-10	60
815	Evaluation of cathepsins D and G and EC 3.4.24.15 as candidate beta-secretase proteases using peptide and amyloid precursor protein substrates. <b>1996</b> , 66, 2436-45	24
814	Generation and regulation of beta-amyloid peptide variants by neurons. <b>1998</b> , 71, 1920-5	97
813	Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. <b>2002</b> , 28, 427-40	29
812	Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. <b>2002</b> , 977, 258-65	22
811	Gamma-secretase: substrates and inhibitors. <b>2002</b> , 26, 81-95	19

810	The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. <b>2002</b> , 2, 1-10	63
809	What can rodent models tell us about cognitive decline in Alzheimer's disease?. <b>2003</b> , 27, 249-76	21
808	Protein phosphorylation and APP metabolism. <b>2003</b> , 28, 1553-61	57
807	Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. <b>2003</b> , 977, 38-45	93
806	Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. <b>2003</b> , 179, 77-82	17
805	Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Abeta-mediated neurotoxicity. <b>2003</b> , 85, 925-34	35
804	Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. <b>2003</b> , 9, 3-4	606
803	Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). <b>2003</b> , 14, 579-94	56
802	Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. <b>2003</b> , 325, 743-57	87
801	Alterations in beta-amyloid production and deposition in brain regions of two transgenic models. <b>2003</b> , 24, 645-53	47
800	Human beta-secretase activity in yeast detected by a novel cellular growth selection system. <b>2003</b> , 1620, 167-78	19
799	Causative and susceptibility genes for Alzheimer's disease: a review. <b>2003</b> , 61, 1-24	241
798	No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. <b>2003</b> , 12, 110-20	37
797	Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. <b>2003</b> , 13, 246-53	185
796	Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. <b>2003</b> , 278, 23648-55	81
795	Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. <b>2003</b> , 278, 16528-33	109
794	Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. <b>2003</b> , 12, 2949-56	67
793	Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. <b>2003</b> , 278, 4458-66	67

792	β-Secretase can cleave amyloid precursor protein fragments independent of γ and β-secretase pre-cutting. <b>2003</b> , 12, 57	
791	BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimer's Disease Therapies. <b>2003</b> , 3, 47-55	
790	Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. <b>2003</b> , 62, 1220-7	165
789	Life situation, coping and quality of life in people with high and low risk of developing Alzheimer's disease. <b>2003</b> , 16, 220-8	7
788	γ-Secretase inhibitors--from molecular probes to new therapeutics?. <b>2003</b> , 41, 99-127	3
787	Neurobiologic Basis of Age-Related Dementing Disorders. <b>2003</b> , 1095-1111	
786	Genetics of early-onset Alzheimer dementia. <b>2003</b> , 3, 497-519	34
785	Analysis of neurons created from wild-type and Alzheimer's mutation knock-in embryonic stem cells by a highly efficient differentiation protocol. <b>2003</b> , 23, 8513-25	18
784	Rat transgenic models with a phenotype of intracellular Aβ accumulation in hippocampus and cortex. <b>2004</b> , 6, 209-19	65
783	Cytokines in neuroinflammation and Alzheimer's disease. <b>2004</b> , 5, 529-34	184
782	Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. <b>2004</b> , 32, 661-8	121
781	Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. <b>2004</b> , 75, 1039-42	93
780	Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. <b>2004</b> , 279, 20296-306	261
779	Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. <b>2004</b> , 279, 10542-50	182
778	Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice. <b>2004</b> , 279, 52535-42	34
777	Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. <b>2004</b> , 19, 2839-46	103
776	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <b>2004</b> , 9, 664-83	228
775	PET imaging of amyloid in Alzheimer's disease. <b>2004</b> , 3, 519-27	358

774	APP induces neuronal apoptosis through APP-BP1-mediated downregulation of beta-catenin. <b>2004</b> , 9, 415-22	22
773	BACE1: the beta-secretase enzyme in Alzheimer's disease. <b>2004</b> , 23, 105-14	252
772	In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. <b>2004</b> , 23, 247-54	103
771	Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. <b>2004</b> , 36, 381-6	196
770	Chasing genes in Alzheimer's and Parkinson's disease. <b>2004</b> , 114, 413-38	39
769	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. <b>2004</b> , 101, 3632-7	432
768	Neuropsychological functions in variant Alzheimer's disease with spastic paraparesis. <b>2004</b> , 218, 29-37	4
767	Hypocapnia induces caspase-3 activation and increases Abeta production. <b>2004</b> , 1, 29-37	31
766	Alzheimer's disease--a sum greater than its parts?. <b>2004</b> , 25, 725-33; discussion 743-6	24
765	Familial Alzheimer disease associated with A713T mutation in APP. <b>2004</b> , 370, 241-3	24
764	Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or over-expressing human acetylcholinesterase. <b>2004</b> , 22, 545-9	8
763	Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. <b>2004</b> , 22, 453-65	109
762	Amyloid and tau protein. <b>2004</b> , 4, S62-S69	
761	Neuropathologie de la maladie d'Alzheimer. <b>2004</b> , 1, 1-15	
760	[Possible mechanisms of A beta(1-40)- or A beta(1-42)-induced cell death and their rescue factors]. <b>2004</b> , 124, 135-43	8
759	Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum. <b>2005</b> , 21, 664-72	49
758	Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice. <b>2005</b> , 15, 110-7	30
757	Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. <b>2005</b> , 58, 147-50	72



756	Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. <b>2005</b> , 5, 3851-8	52
755	Genes involved in Alzheimer's disease, a survey of possible candidates. <b>2005</b> , 7, 331-53	29
754	Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease. <b>2005</b> , 11, 3363-82	49
753	Characterization of Drosophila aspartic proteases that induce the secretion of a Golgi-resident transferase, heparan sulfate 6-O-sulfotransferase. <b>2005</b> , 137, 315-22	8
752	Secretase, APP and A $\beta$ in Alzheimer's Disease. <b>2005</b> , 79-103	44
751	Amyloid Precursor Protein and Ferritin Translation: Implications for Metals and Alzheimer's Disease Therapeutics. <b>2005</b> , 215-251	2
750	Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. <b>2005</b> , 14, 1385-409	51
749	Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. <b>2005</b> , 25, 10874-83	202
748	Alzheimer's Disease. <b>2005</b> ,	7
747	Functional overexpression of gamma-secretase reveals protease-independent trafficking functions and a critical role of lipids for protease activity. <b>2005</b> , 280, 12523-35	34
746	Translational research on the way to effective therapy for Alzheimer disease. <b>2005</b> , 62, 1186-92	42
745	A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings. <b>2005</b> , 102, 14854-9	39
744	Therapeutic potential of small interfering RNA for central nervous system diseases. <b>2005</b> , 62, 1810-3	13
743	Effects of statins on microglia. <b>2005</b> , 82, 10-9	42
742	beta-site specific intrabodies to decrease and prevent generation of Alzheimer's A $\beta$ peptide. <b>2005</b> , 168, 863-8	92
741	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. <b>2005</b> , 20, 625-37	65
740	Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid. <b>2005</b> , 1739, 116-24	25
739	High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. <b>2005</b> , 192, 215-25	105

738	Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. <b>2005</b> , 167, 505-15	150
737	Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. <b>2005</b> , 130, 339-47	64
736	Endogenous beta-amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. <b>2005</b> , 135, 1193-202	23
735	Alzheimer: 100 Years and Beyond. <b>2006</b> ,	5
734	[New therapeutic approaches in Alzheimer disease]. <b>2006</b> , 32 Pt 5, S641-9	0
733	Calcium and Neuronal Injury in Alzheimer's Disease. <b>2006</b> , 747, 50-76	112
732	Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations. <b>2006</b> , 371, 68-74	25
731	Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. <b>2006</b> , 24, 269-73	7
730	A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation. <b>2006</b> , 88, 282-92	13
729	The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. <b>2006</b> , 27, 67-77	185
728	Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. <b>2006</b> , 27, 614-23	60
727	Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice. <b>2006</b> , 27, 946-54	39
726	A hundred years of Alzheimer's disease research. <b>2006</b> , 52, 3-13	365
725	Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. <b>2006</b> , 9, 329-39	18
724	Animal Models of Alzheimer's Disease. <b>2006</b> , 1-73	
723	Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. <b>2002</b> , 12, 275-86	104
722	Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. <b>2006</b> , 16, 40-54	130
721	Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. <b>2006</b> , 98, 1610-8	55

720	Nicotinic cholinergic modulation: galantamine as a prototype. <b>2002</b> , 8, 405-26	39
719	Transgenic mouse models of Alzheimer's disease. <b>2000</b> , 908, 260-6	68
718	Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. <b>2000</b> , 920, 134-9	112
717	The value of transgenic models for the study of neurodegenerative diseases. <b>2000</b> , 920, 179-91	44
716	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. <b>2006</b> , 63, 1538-52	74
715	Development of new screening system for Alzheimer disease, in vitro Abeta sink assay, to identify the dissociation of soluble Abeta from fibrils. <b>2006</b> , 22, 487-95	7
714	Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. <b>2006</b> , 24, 475-83	54
713	Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. <b>2006</b> , 27, 888-96	54
712	Alzheimer Disease: What Role for Leptin and Insulin?. <b>2006</b> , 6, 271-279	1
711	Vaccine development for Alzheimer's disease. <b>2006</b> , 12, 4283-93	13
710	Genetically modified mice models for Alzheimer's disease. <b>2006</b> , 6, 609-27	13
709	Candidate susceptibility genes in Alzheimer's disease are at high risk for being forgotten-- they don't give peace of mind. <b>2006</b> , 7, 273-93	11
708	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. <b>2006</b> , 17, 429-54	25
707	Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. <b>2006</b> , 26, 10129-40	1834
706	Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. <b>2007</b> , 27, 3639-49	286
705	GSK3beta activity modifies the localization and function of presenilin 1. <b>2007</b> , 282, 15823-32	68
704	A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. <b>2007</b> , 27, 14459-69	266
703	Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. <b>2007</b> , 72, 141-51	30

702	Beta-amyloid modulation of synaptic transmission and plasticity. <b>2007</b> , 27, 11832-7	94
701	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. <b>2007</b> , 30, 1-32	
700	Maladie d'Alzheimer. <b>2007</b> , 4, 1-26	0
699	Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice. <b>2007</b> , 28, 75-84	14
698	Intracellular Aβ and cognitive deficits precede beta-amyloid deposition in transgenic arcAβ mice. <b>2007</b> , 28, 1297-306	196
697	Amyloid beta inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor. <b>2007</b> , 145, 5-10	26
696	Alzheimer disease: amyloidogenesis, the presenilins and animal models. <b>2007</b> , 1772, 285-97	82
695	A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation. <b>2007</b> , 358, 777-82	31
694	Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. <b>2007</b> , 103, 334-45	122
693	An update on the amyloid hypothesis. <b>2007</b> , 25, 669-82, vi	34
692	Morbo di Alzheimer. <b>2007</b> , 7, 1-26	
691	Concept of disease in geriatric psychiatry. <b>2007</b> , 15, 1-11	7
690	Amyloid-beta aggregation. <b>2007</b> , 4, 13-27	244
689	The Molecular Basis of Alzheimer's Disease. <b>2007</b> , 241-255	
688	Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels. <b>2007</b> , 2, 11	56
687	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. <b>2007</b> , 8, 101-12	3692
686	Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. <b>2007</b> , 14, 2047-57	28
685	Impairment of hippocampal gamma-frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). <b>2007</b> , 26, 1280-8	59

684	Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. <b>2007</b> , 26, 882-9	37
683	The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. <b>2007</b> , 101, 854-62	46
682	Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. <b>2007</b> , 102, 619-26	22
681	High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. <b>2007</b> , 103, 216-28	30
680	Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw). <b>2007</b> , 1185, 45-58	15
679	Binding of the Alzheimer amyloid beta-peptide to neuronal cell membranes by fluorescence correlation spectroscopy. <b>2007</b> , 82, 169-74	14
678	BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. <b>2007</b> , 26, 134-45	236
677	The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. <b>2007</b> , 35, 574-6	51
676	Behavior of neural stem cells in the Alzheimer brain. <b>2008</b> , 65, 2372-84	76
675	Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease. <b>2008</b> , 35 Suppl 1, S107-13	23
674	Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. <b>2008</b> , 116, 409-18	17
673	Ca <sup>2+</sup> channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. <b>1994</b> , 62, 372-5	173
672	A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. <b>2008</b> , 63, 377-87	329
671	Pharmacogenomics in Alzheimer's disease. <b>2008</b> , 448, 213-357	72
670	Animal models of Alzheimer's disease and frontotemporal dementia. <b>2008</b> , 9, 532-44	535
669	Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. <b>2008</b> , 16, 171-5	17
668	Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. <b>2008</b> , 18, 548-61	62
667	Mutational screening of APP gene in patients with early-onset Alzheimer disease utilizing mismatched PCR-RFLP. <b>1996</b> , 49, 119-23	5

666	CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice. <b>2008</b> , 1231, 132-42	10
665	A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis. <b>2008</b> , 181, 52-4	6
664	Fatty acids, lipid metabolism and Alzheimer pathology. <b>2008</b> , 585, 176-96	71
663	Advances in Alzheimer's and Parkinson's Disease. <b>2008</b> ,	
662	Pharmacogenomics in drug discovery and development. Preface. <b>2008</b> , 448, v-vii	5
661	Central Nervous System Diseases and Inflammation. <b>2008</b> ,	5
660	Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase. <b>2008</b> , 54, 998-1005	15
659	Beta-amyloid and glutamate receptors. <b>2008</b> , 212, 1-4	18
658	Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. <b>2008</b> , 374, 673-8	75
657	Dementia of the Alzheimer type. <b>2008</b> , 30, 15-34	94
656	Drug Targets, Target identification, Validation and Screening. <b>2008</b> , 106-121	0
655	The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. <b>2008</b> , 283, 34554-62	79
654	Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. <b>1999</b> , 72, 1161-9	51
653	Molecular genetics of Alzheimer's disease: an update. <b>2008</b> , 40, 562-83	175
652	Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. <b>2008</b> , 65, 499-505	78
651	A method in enzymology for measuring hydrolytic activities in live cell environments. <b>2008</b> , 450, 1-19	5
650	[Treatment of Alzheimer's disease: status quo and future considerations]. <b>2008</b> , 131, 351-6	1
649	Prevention of amyloid $\beta$ -induced memory impairment by fluvastatin, associated with the decrease in amyloid $\beta$ -accumulation and oxidative stress in amyloid $\beta$ -injection mouse model. <b>2008</b> ,	2

648	Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. <b>2008</b> , 3, e2248	40
647	Hereditary forms of cerebrovascular amyloidosis. 139-154	
646	Influência genética sobre a doença de Alzheimer de início precoce. <b>2009</b> , 36, 25-30	2
645	Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease. <b>2009</b> , 28, 521-7	18
644	Residues at P2-P1 positions of epsilon- and zeta-cleavage sites are important in formation of beta-amyloid peptide. <b>2009</b> , 36, 453-60	2
643	Sumoylation and human disease pathogenesis. <b>2009</b> , 34, 200-5	115
642	CD40/CD40L interaction induces A $\beta$ production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. <b>2009</b> , 315, 2265-74	7
641	Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer's disease. <b>2010</b> , 14, 1816-23	20
640	Microsatellite D21S210 (GT-12) allele frequencies in sporadic Alzheimer's disease. <b>1995</b> , 91, 145-8	
639	Lack of point mutation of the APP gene in sporadic Alzheimer's disease in Japanese. <b>1996</b> , 93, 138-41	1
638	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. <b>2009</b> , 118, 115-30	212
637	Hemizygous minipigs produced by random gene insertion and handmade cloning express the Alzheimer's disease-causing dominant mutation APP <sup>sw</sup> . <b>2009</b> , 18, 545-58	133
636	Endogenously generated amyloid $\beta$ increases membrane fluidity in neural 2a cells. <b>2009</b> , 54, 394-398	2
635	What is 'early onset dementia'?. <b>2009</b> , 9, 67-72	21
634	Studying the pathogenesis of Alzheimer's disease in a Drosophila melanogaster model: Human APP overexpression in the brain of transgenic flies leads to deficit of the synaptic protein synaptotagmin. <b>2009</b> , 45, 105-112	2
633	Effect of amyloid beta on capacitive calcium entry in neural 2a cells. <b>2009</b> , 78, 152-7	14
632	Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. <b>2009</b> , 1790, 615-28	72
631	Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. <b>2009</b> , 175, 2557-65	301

630	Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. <b>2010</b> , 69, 53-9	37
629	Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. <b>2010</b> , 67, 581-600	43
628	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. <b>2010</b> , 120, 369-84	105
627	The role of microglia in amyloid clearance from the AD brain. <b>2010</b> , 117, 949-60	393
626	Presenilins and the gamma-secretase: still a complex problem. <b>2010</b> , 3, 7	18
625	Searching for new animal models of Alzheimer's disease. <b>2010</b> , 626, 57-63	36
624	Skin and brain age together: The role of hormones in the ageing process. <b>2010</b> , 45, 801-13	72
623	Kynurenines, neurodegeneration and Alzheimer's disease. <b>2010</b> , 14, 2045-54	46
622	Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. <b>2010</b> , 24, 182-6	45
621	BACE1 and BACE2 enzymatic activities in Alzheimer's disease. <b>2010</b> , 112, 1045-53	79
620	Animal models of amyloid-beta-related pathologies in Alzheimer's disease. <b>2010</b> , 277, 1389-409	74
619	The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of A $\beta$ in different brain regions. <b>2010</b> , 18, 1202-8	25
618	Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. <b>2010</b> , 68 Suppl 2, S128-34	2
617	BACE, APP Processing, and Signal Transduction in Alzheimer's Disease. 1-13	1
616	. <b>2010</b> ,	4
615	A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. <b>2010</b> , 20, 113-26	142
614	Ascidians: an invertebrate chordate model to study Alzheimer's disease pathogenesis. <b>2010</b> , 3, 377-85	17
613	Aging-Related Memory Disorders Alzheimer's Disease. <b>2010</b> , 292-319	1



612	Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. <b>2010</b> , 285, 7619-32	131
611	Correlating familial Alzheimer's disease gene mutations with clinical phenotype. <b>2010</b> , 4, 99-112	113
610	Pathophysiology of the vascular wall and its relevance for cerebrovascular disorders in aged rodents. <b>2010</b> , 7, 251-67	23
609	Identification of BACE as a Target in Alzheimer's Disease. 15-33	1
608	Amyloid precursor protein gene mutated at Swedish 670/671 sites in vitro induces changed expression of nicotinic acetylcholine receptors and neurotoxicity. <b>2010</b> , 57, 647-54	8
607	APP(DeltaNL695) expression in murine tissue downregulates CNBP expression. <b>2010</b> , 482, 57-61	10
606	Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. <b>2010</b> , 398, 337-41	46
605	Probing the biology of Alzheimer's disease in mice. <b>2010</b> , 66, 631-45	334
604	REVIEW: Curcumin and Alzheimer's disease. <b>2010</b> , 16, 285-97	295
603	Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. <b>2010</b> , 9, 3574-82	43
602	BACE: A (Almost) Perfect Target for Staving off Alzheimer's Disease. <b>2011</b> , 391-412	1
601	SUMO and its role in human diseases. <b>2011</b> , 288, 167-83	60
600	Stem Cells & Regenerative Medicine. <b>2011</b> ,	5
599	The cysteine protease inhibitor, E64d, reduces brain amyloid- $\beta$ and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, $\beta$ secretase activity. <b>2011</b> , 26, 387-408	70
598	Biomarker-based dissection of neurodegenerative diseases. <b>2011</b> , 95, 520-34	66
597	Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. <b>2011</b> , 32, 280-92	32
596	The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimer's disease. <b>2011</b> , 2011, 296374	8
595	Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. <b>2011</b> , 66 Suppl 1, 45-54	73

594	Amyloid- $\beta$ protein precursor family members: a review from homology to biological function. <b>2011</b> , 26, 607-26	9
593	Targets for AD treatment: conflicting messages from $\beta$ secretase inhibitors. <b>2011</b> , 117, 359-74	49
592	Alzheimer's disease: the challenge of the second century. <b>2011</b> , 3, 77sr1	893
591	Transgenic animal models of neurodegeneration based on human genetic studies. <b>2011</b> , 118, 27-45	29
590	APP transgenic mice: their use and limitations. <b>2011</b> , 13, 117-37	54
589	Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient. <b>2011</b> , 4, 476	15
588	BACE-1 inhibition prevents the $\beta$ secretase inhibitor evoked A $\beta$ rise in human neuroblastoma SH-SY5Y cells. <b>2011</b> , 18, 76	19
587	Transgenic mice as a model of pre-clinical Alzheimer's disease. <b>2011</b> , 8, 4-23	38
586	Transgenic mice as a model for Alzheimer's disease. <b>2011</b> , 8, 818-31	25
585	Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. <b>2011</b> , 52, 1004-10	73
584	Emerging roles of pathogens in Alzheimer disease. <b>2011</b> , 13, e30	119
583	ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1. <b>2011</b> , 108, E559-68	169
582	Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. <b>2011</b> , 286, 33489-500	42
581	Encephalopathy with amyloid angiopathy and numerous amyloid plaques with low levels of CSF A $\beta$ -40/A $\beta$ -42. <b>2012</b> , 19, 186-90	3
580	Trafficking and proteolytic processing of APP. <b>2012</b> , 2, a006270	628
579	WITHDRAWN: Protein sumoylation and human diseases. <b>2012</b> ,	
578	Early impairment of long-term depression in the perirhinal cortex of a mouse model of Alzheimer's disease. <b>2012</b> , 15, 231-4	20
577	Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-A $\beta$ APP mutation. <b>2012</b> , 2, e183	38

576	Cdk5 protein inhibition and A $\beta$ 2 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. <b>2012</b> , 287, 7224-35	48
575	Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2. <b>2012</b> , 393, 473-84	12
574	Enhanced $\beta$ secretase processing alters APP axonal transport and leads to axonal defects. <b>2012</b> , 21, 4587-601	43
573	Recognition memory and $\beta$ amyloid plaques in adult Tg2576 mice are not modified after oral exposure to aluminum. <b>2012</b> , 26, 179-85	11
572	Butyrylcholinesterase is associated with $\beta$ amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. <b>2012</b> , 71, 2-14	93
571	Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. <b>2012</b> , 18, 1131-47	104
570	Amyloid and Alzheimer's disease: inside and out. <b>2012</b> , 39, 286-98	50
569	Amyloid- $\beta$ metabolism in Niemann-Pick C disease models and patients. <b>2012</b> , 27, 573-85	35
568	Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. <b>2012</b> , 4, 9	103
567	Cerebral amyloid angiopathy. <b>2012</b> , 107, 41-78	47
566	Different $\beta$ amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <b>2012</b> , 33, 825.e1-13	76
565	A $\beta$ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. <b>2012</b> , 3, 1009	51
564	Conformational analysis of amyloid precursor protein fragment containing amino acids 667-676, and the effect of D-Asp and iso-Asp substitution at Asp175 residue. <b>2012</b> , 177, 621-9	7
563	Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. <b>2012</b> , 228, 392-7	35
562	Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease. <b>2012</b> , 501, 63-78	7
561	Alzheimer's disease and the amyloid $\beta$ protein. <b>2012</b> , 107, 101-24	96
560	Genetic animal models of cerebral vasculopathies. <b>2012</b> , 105, 25-55	13
559	Synaptic dysfunction in Alzheimer's disease. <b>2012</b> , 970, 573-601	79

558	Effects of NK-4 in a transgenic mouse model of Alzheimer's disease. <b>2012</b> , 7, e30007	12
557	Differential regulation of amyloid precursor protein/presenilin 1 interaction during A $\beta$ 0/42 [corrected] production detected using fusion constructs. <b>2012</b> , 7, e48551	4
556	The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. <b>2012</b> , 3, 8	53
555	Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. <b>2012</b> , 17, 2024-34	31
554	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. <b>2012</b> , 112, 5147-92	636
553	Genetics of dementia: update and guidelines for the clinician. <b>2012</b> , 159B, 628-43	33
552	The role of APP and APLP for synaptic transmission, plasticity, and network function: lessons from genetic mouse models. <b>2012</b> , 217, 435-40	42
551	Genetically modified pigs for biomedical research. <b>2012</b> , 35, 695-713	79
550	Twenty years of Alzheimer's disease-causing mutations. <b>2012</b> , 120 Suppl 1, 3-8	108
549	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. <b>2012</b> , 134, 8-25	153
548	Neuron loss in the 5XFAD mouse model of Alzheimer's disease correlates with intraneuronal A $\beta$ 2 accumulation and Caspase-3 activation. <b>2013</b> , 8, 2	191
547	Amyloid- $\beta$ protein (A $\beta$ ) Glu11 is the major $\beta$ -secretase site of $\beta$ -site amyloid- $\beta$ precursor protein-cleaving enzyme 1 (BACE1), and shifting the cleavage site to A $\beta$ Asp1 contributes to Alzheimer pathogenesis. <b>2013</b> , 37, 1962-9	53
546	Amplified voltammetric characterization of cleavage of the biotinylated peptide by BACE1 and screening of BACE1 inhibitors. <b>2013</b> , 50, 224-8	10
545	The Kunitz-protease inhibitor domain in amyloid precursor protein reduces cellular mitochondrial enzymes expression and function. <b>2013</b> , 437, 642-7	11
544	Synaptic changes in Alzheimer's disease and its models. <b>2013</b> , 251, 51-65	206
543	Pharmacologic inhibition of ROCK2 suppresses amyloid- $\beta$ production in an Alzheimer's disease mouse model. <b>2013</b> , 33, 19086-98	98
542	Trait'sur la maladie d'Alzheimer. <b>2013</b> ,	
541	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. <b>2013</b> , 1, 56	31

540	[Genetic aspects of Alzheimer's disease (Review)]. <b>2013</b> , 61, 228-38	4
539	Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid- $\beta$ proteins in the cerebral vasculature. <b>2013</b> , 10, 1557-65	17
538	Sorting receptor SORLA--a trafficking path to avoid Alzheimer disease. <b>2013</b> , 126, 2751-60	80
537	$\beta$ Secretase: its biology as a therapeutic target in diseases. <b>2013</b> , 34, 215-25	54
536	Amyloidogenesis, Neurogenesis, Learning, and Memory in Alzheimer's Disease: Lessons from Transgenic Mouse Models. <b>2013</b> , 157-186	
535	Establishment of experimental models for Alzheimer's disease research. <b>2013</b> , 123, 823-31	5
534	Amyloid $\beta$ protein oligomers and Alzheimer's disease. <b>2013</b> , 5, 60	150
533	Sensitive and continuous screening of inhibitors of $\beta$ site amyloid precursor protein cleaving enzyme 1 (BACE1) at single SPR chips. <b>2013</b> , 85, 3660-6	34
532	The role of APP and BACE1 trafficking in APP processing and amyloid- $\beta$ generation. <b>2013</b> , 5, 46	76
531	Specific uptake of an amyloid- $\beta$ protofibril-binding antibody-tracer in APP transgenic mouse brain. <b>2013</b> , 37, 29-40	43
530	Early endosomal abnormalities and cholinergic neuron degeneration in amyloid- $\beta$ protein precursor transgenic mice. <b>2013</b> , 34, 691-700	26
529	Hereditary and sporadic beta-amyloidoses. <b>2013</b> , 18, 1202-26	6
528	Gpr3 stimulates A $\beta$ production via interactions with APP and $\beta$ arrestin2. <b>2013</b> , 8, e74680	24
527	Visualization and quantification of APP intracellular domain-mediated nuclear signaling by bimolecular fluorescence complementation. <b>2013</b> , 8, e76094	9
526	Modeling Alzheimer's disease: from past to future. <b>2013</b> , 4, 77	30
525	The Continuum of Metabolic Stress According to the Gas Model of Alzheimer's Disease. <b>2014</b> , 04,	
524	Genetic inhibition of phosphorylation of the translation initiation factor eIF2 $\beta$ does not block A $\beta$ dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease. <b>2014</b> , 9, e101643	29
523	Early onset Alzheimer's disease and oxidative stress. <b>2014</b> , 2014, 375968	35

522	Clinical genetics of Alzheimer's disease. <b>2014</b> , 2014, 291862	31
521	New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. <b>2014</b> , 8, 235	73
520	Genetics of Alzheimer's Disease. <b>2014</b> ,	
519	A $\beta$ 8 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models. <b>2014</b> , 39, 871-81	19
518	Biomarkers of Alzheimer's disease. <b>2014</b> , 801-815	
517	A synthetic antibody fragment targeting nicastrin affects assembly and trafficking of $\beta$ secretase. <b>2014</b> , 289, 34851-61	5
516	Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase. <b>2014</b> , 9, 1	86
515	Combining BACE1 Inhibition with Metal Chelation as Possible Therapy for Alzheimer's Disease. <b>2014</b> , 547-565	
514	Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. <b>2014</b> , 130, 4-28	232
513	$\beta$ Amyloid pathology alters neural network activation during retrieval of contextual fear memories in a mouse model of Alzheimer's disease. <b>2014</b> , 39, 1690-703	5
512	Amyloid- $\beta$ -directed immunotherapy for Alzheimer's disease. <b>2014</b> , 275, 284-95	106
511	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. <b>2014</b> , 6, 89	279
510	Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer's disease. <b>2014</b> , 9, e94576	22
509	Critical analysis of the use of $\beta$ site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. <b>2014</b> , 4, 1-19	3
508	Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. <b>2014</b> , 88, 450-67	119
507	Neurodegenerative Diseases. <b>2014</b> ,	2
506	Tau phosphorylation and tau mislocalization mediate soluble A $\beta$ oligomer-induced AMPA glutamate receptor signaling deficits. <b>2014</b> , 39, 1214-24	76
505	Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. <b>2014</b> , 9, 42	87

504	Genetics of Alzheimer's disease. <b>2014</b> , 87, 245-94	134
503	The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid- $\beta$ aggregation. <b>2014</b> , 289, 30977-89	116
502	Novel APP K724M mutation causes Chinese early-onset familial Alzheimer's disease and increases amyloid- $\beta$ 2 to amyloid- $\beta$ 40 ratio. <b>2014</b> , 35, 2657.e1-2657.e6	13
501	Distinct synthetic A $\beta$ prion strains producing different amyloid deposits in bigenic mice. <b>2014</b> , 111, 10329-34	124
500	CSF in Alzheimer's disease. <b>2014</b> , 65, 143-72	18
499	Perspectives on future Alzheimer therapies: amyloid- $\beta$ protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. <b>2014</b> , 6, 16	96
498	Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. <b>2014</b> , 14, 169	50
497	The Amyloid Precursor Protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid. <b>2014</b> , 7, 54	46
496	BACE1 ( $\beta$ secretase) inhibitors for the treatment of Alzheimer's disease. <b>2014</b> , 43, 6765-813	232
495	Secreted amyloid $\beta$ proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. <b>2014</b> , 53, 3908-21	71
494	Serial propagation of distinct strains of A $\beta$ prions from Alzheimer's disease patients. <b>2014</b> , 111, 10323-8	214
493	Alzheimer's disease genetics: from the bench to the clinic. <b>2014</b> , 83, 11-26	308
492	Rare Variants and Transcriptomics in Alzheimer disease. <b>2014</b> , 2, 75-84	9
491	Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease. <b>2014</b> , 11, 84	11
490	Abundance of A $\beta$ x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. <b>2014</b> , 9, 13	18
489	Brainwide distribution and variance of amyloid-beta deposits in tg-ArcSwe mice. <b>2014</b> , 35, 556-64	12
488	Imatinib treatment and A $\beta$ 2 in humans. <b>2014</b> , 10, S374-80	10
487	Targeting the $\beta$ secretase BACE1 for Alzheimer's disease therapy. <b>2014</b> , 13, 319-29	438

486	Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease. <b>2015</b> , 43, 1393-402	20
485	Structural Magnetic Resonance Imaging Markers of Alzheimer's Disease and Its Retranslation to Rodent Models. <b>2015</b> , 47, 277-90	5
484	Peripheral amyloid levels present gender differences associated with aging in APP/PS1 mice. <b>2015</b> , 44, 1063-8	28
483	Significance of transcytosis in Alzheimer's disease: BACE1 takes the scenic route to axons. <b>2015</b> , 37, 888-98	8
482	APP intracellular domain derived from amyloidogenic $\beta$ and $\beta$ secretase cleavage regulates neprilysin expression. <b>2015</b> , 7, 77	37
481	Epigenetic Alterations in Alzheimer's Disease. <b>2015</b> , 9, 347	92
480	Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease. <b>2015</b> , 10, e0119910	40
479	High Fat Diet Enhances $\beta$ Site Cleavage of Amyloid Precursor Protein (APP) via Promoting $\beta$ Site APP Cleaving Enzyme 1/Adaptor Protein 2/Clathrin Complex Formation. <b>2015</b> , 10, e0131199	29
478	Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease. <b>2015</b> , 2015, 393510	8
477	Rarity of the Alzheimer disease-protective APP A673T variant in the United States. <b>2015</b> , 72, 209-16	31
476	Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau. <b>2015</b> , 129, 895-907	50
475	White matter changes in familial Alzheimer's disease. <b>2015</b> , 278, 211-8	20
474	Reduction of $\beta$ amyloid and $\beta$ secretase by calorie restriction in female Tg2576 mice. <b>2015</b> , 36, 1293-302	58
473	Cerebrospinal Fluid in Clinical Neurology. <b>2015</b> ,	13
472	Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. <b>2015</b> , 15, 339-48	34
471	A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. <b>2015</b> , 10, 633-44	164
470	The potent BACE1 inhibitor LY2886721 elicits robust central $\text{Al}\beta$ pharmacodynamic responses in mice, dogs, and humans. <b>2015</b> , 35, 1199-210	132
469	Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases. <b>2015</b> , 121, 59-86	5



468	The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model. <b>2015</b> , 287, 96-9	36
467	A simple and label-free electrochemical method for detection of beta-site amyloid precursor protein cleaving enzyme and screening of its inhibitor. <b>2015</b> , 213, 111-115	16
466	The role and therapeutic targeting of $\beta$ and $\beta$ secretase in Alzheimer's disease. <b>2015</b> , 1, FSO11	53
465	Overexpression of heparanase lowers the amyloid burden in amyloid- $\beta$ precursor protein transgenic mice. <b>2015</b> , 290, 5053-5064	36
464	Extra-virgin olive oil attenuates amyloid- $\beta$ and tau pathologies in the brains of TgSwDI mice. <b>2015</b> , 26, 1479-90	60
463	The Role of Tissue Non-specific Alkaline Phosphatase (TNAP) in Neurodegenerative Diseases: Alzheimer's Disease in the Focus. <b>2015</b> , 76, 363-74	14
462	Histone deacetylases (HDACs) and brain function. <b>2015</b> , 1, 20-27	97
461	Tau aggregation and its interplay with amyloid- $\beta$ <b>2015</b> , 129, 207-20	222
460	Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid- $\beta$ levels in APP/PS1 transgenic mice. <b>2015</b> , 11, 421-30	51
459	Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. <b>2015</b> , 12, 49-56	70
458	The Arctic mutation accelerates A $\beta$ aggregation in SDS through reducing the helical propensity of residues 15-25. <b>2015</b> , 22, 8-18	7
457	Role of BACE1 in Cognitive Function, from Alzheimer's Disease to Traumatic Brain Injury. <b>2016</b> , 239-266	
456	Neurodefensive Effect of Olea europaea L. in Alloxan-Induced Cognitive Dysfunction and Brain Tissue Oxidative Stress in Mice: Incredible Natural Nootropic. <b>2016</b> , 7,	6
455	Genes associated with Alzheimer's disease: an overview and current status. <b>2016</b> , 11, 665-81	161
454	. <b>2016</b> ,	18
453	The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders. <b>2016</b> , 36, 845-70	80
452	Common and Rare Genetic Variants Associated With Alzheimer's Disease. <b>2016</b> , 231, 1432-7	10
451	Immunotherapy targeting pyroglutamate-3 A $\beta$ prospects and challenges. <b>2016</b> , 11, 48	28

450	Expression of the Alzheimer's Disease Mutations A $\beta$ P695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs. <b>2016</b> , 53, 1617-30	20
449	Design and Enabling Development of Hydroxyethylamine-Derived BACE1 Inhibitor. <b>2016</b> , 137-170	
448	A $\beta$ P/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging. <b>2016</b> , 54, 645-56	19
447	Deposition of C-terminally truncated A $\beta$ species A $\beta$ 7 and A $\beta$ 9 in Alzheimer's disease and transgenic mouse models. <b>2016</b> , 4, 24	22
446	Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A $\beta$ generation in Alzheimer's disease. <b>2016</b> , 132, 235-256	121
445	A signal-on electrochemical strategy for protease detection based on the formation of ATCUN-Cu(II). <b>2016</b> , 232, 557-563	9
444	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease. <b>2016</b> , 153-179	
443	Immunotherapy and Biomarkers in Neurodegenerative Disorders. <b>2016</b> ,	3
442	Genomics of Alzheimer Disease: A Review. <b>2016</b> , 73, 867-74	83
441	The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update. <b>2016</b> , 60, 325-335	41
440	$\alpha$ -Nicotinic Acetylcholine Receptors and $\beta$ -Amyloid Peptides in Alzheimer's Disease. <b>2016</b> , 171-205	1
439	Alternative Selection of $\beta$ -Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid $\beta$ -Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the A $\beta$ Sequence. <b>2016</b> , 291, 24041-24053	49
438	Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System. <b>2016</b> , 60, 305-315	34
437	Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid $\beta$ -peptide production. <b>2016</b> , 20, 1686-95	96
436	BACE Inhibitors. <b>2016</b> , 327-354	2
435	Immunotherapy Against Amyloid- $\beta$ Protofibrils: Opportunities and Challenges. <b>2016</b> , 51-60	
434	Pathogenic mechanisms of prion protein, amyloid- $\beta$ and $\alpha$ -Synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. <b>2016</b> , 139, 162-180	59
433	AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. <b>2017</b> , 55, 1039-1053	58

432	Integration of common feature pharmacophore modeling and in vitro study to identify potent AChE inhibitors. <b>2016</b> , 25, 2965-2975	4
431	Phosphatidylethanolamine Metabolism in Health and Disease. <b>2016</b> , 321, 29-88	125
430	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <b>2016</b> , 53, 349-61	6
429	Therapeutic Targeting of A $\beta$ 2. <b>2016</b> , 77-96	
428	Secretase Inhibition. <b>2016</b> , 39-62	1
427	Infliximab ameliorates AD-associated object recognition memory impairment. <b>2016</b> , 311, 384-391	21
426	A role for $\alpha$ * nicotinic receptors in a model of local amyloid pathology induced in dentate gyrus. <b>2016</b> , 46, 221-34	3
425	Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. <b>2016</b> , 37, 1403-35	47
424	Alzheimer's disease due to loss of function: A new synthesis of the available data. <b>2016</b> , 143, 36-60	85
423	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease. <b>2016</b> , 53, 905-931	61
422	Detection of Cyclooxygenase-1 in Activated Microglia During Amyloid Plaque Progression: PET Studies in Alzheimer's Disease Model Mice. <b>2016</b> , 57, 291-6	31
421	Studying infrared light therapy for treating Alzheimer's disease. <b>2016</b> ,	1
420	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. <b>2016</b> , 77-111	
419	A graphene oxide-based fluorescent scheme for the determination of the activity of the B-site amyloid precursor protein (BACE1) and its inhibitors. <b>2016</b> , 183, 265-271	15
418	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer's and Parkinson's Diseases. <b>2016</b> , 293-325	1
417	Biomedical Engineering: Frontier Research and Converging Technologies. <b>2016</b> ,	
416	Stem Cells in Alzheimer's Disease Therapy. <b>2017</b> , 49-64	
415	Effects of Nobiletin in Animal Models of Cognitive Impairment. <b>2017</b> , 421-433	

414	Predicting Cognitive Decline across Four Decades in Mutation Carriers and Non-carriers in Autosomal-Dominant Alzheimer's Disease. <b>2017</b> , 23, 195-203	10
413	The effects of different familial Alzheimer's disease mutations on APP processing in vivo. <b>2017</b> , 9, 9	22
412	Platelets and Neurodegenerative Diseases. <b>2017</b> , 1209-1224	1
411	Evaluation of the Expression of Amyloid Precursor Protein and the Ratio of Secreted Amyloid Beta 42 to Amyloid Beta 40 in SH-SY5Y Cells Stably Transfected with Wild-Type, Single-Mutant and Double-Mutant Forms of the APP Gene for the Study of Alzheimer's Disease Pathology. <b>2017</b> , 183, 853-866	10
410	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. <b>2017</b> , 9, 731-748	9
409	Retinal changes in the Tg-SwDI mouse model of Alzheimer's disease. <b>2017</b> , 354, 43-53	8
408	BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A $\beta$ Peptides. <b>2017</b> , 57, 1460-1471	32
407	State of Play in Alzheimer's Disease Genetics. <b>2017</b> , 58, 631-659	29
406	BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis. <b>2017</b> , 37, 6915-6925	57
405	Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A $\beta$ 2 and A $\beta$ 0 peptides by $\beta$ secretase. <b>2017</b> , 114, E476-E485	173
404	The Effects of Gene Mutations on 'Default' Mode Network in 'Familial' Alzheimer's Disease. <b>2017</b> , 56, 327-334	7
403	Genetics of $\beta$ Amyloid Precursor Protein in Alzheimer's Disease. <b>2017</b> , 7,	63
402	Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease. <b>2017</b> , 73, 340-358	20
401	M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. <b>2017</b> , 114, E9135-E9144	34
400	Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease. <b>2017</b> , 114, E9665-E9674	29
399	Amyloid precursor protein drives down-regulation of mitochondrial oxidative phosphorylation independent of amyloid beta. <b>2017</b> , 7, 9835	18
398	BACE1 Deficiency Causes Abnormal Neuronal Clustering in the Dentate Gyrus. <b>2017</b> , 9, 217-230	3
397	Large Scale Medical Data Mining for Accurate Diagnosis: A Blueprint. <b>2017</b> , 157-176	13

396	Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. <b>2017</b> , 8, 1403	31
395	Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. <b>2017</b> , 114, E6962-E6971	66
394	Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid Load and Related Toxicity in 5XFAD Mice. <b>2017</b> , 8, 1756-1766	44
393	Inference of Causative Genes for Alzheimer's Disease Due to Dosage Imbalance. <b>2017</b> , 34, 2396-2407	11
392	Engramigenetics: Epigenetics of engram memory cells. <b>2017</b> , 325, 297-302	5
391	Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to Secretase-Mediated Processing of the Amyloid-Protein Precursor: Utility of an APP-GAL4 Reporter Assay. <b>2018</b> , 61, 673-688	6
390	Nephrilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts. <b>2017</b> , 40, 327-333	14
389	Perplexity of Amyloid Protein Oligomer Formation: Relevance to Alzheimer's Disease. <b>2017</b> , 1-50	3
388	The integration site of the transgene in the J20 mouse model of Alzheimer's disease. <b>2017</b> , 2, 84	10
387	Amyloid Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease. <b>2017</b> , 109-143	5
386	Alzheimer's Disease: From Genetic Variants to the Distinct Pathological Mechanisms. <b>2017</b> , 10, 319	23
385	Practical considerations for choosing a mouse model of Alzheimer's disease. <b>2017</b> , 12, 89	189
384	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <b>2017</b> , 93, 757-771	24
383	How Surrogate and Chemical Genetics in Model Organisms Can Suggest Therapies for Human Genetic Diseases. <b>2018</b> , 208, 833-851	10
382	Toward Secretase-1 Inhibitors with Improved Isoform Selectivity. <b>2018</b> , 61, 3491-3502	18
381	High fat diet treatment impairs hippocampal long-term potentiation without alterations of the core neuropathological features of Alzheimer disease. <b>2018</b> , 113, 82-96	21
380	BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions. <b>2018</b> , 215, 927-940	65
379	AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. <b>2018</b> , 14, 811-823	26

378	Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. <b>2018</b> , 7, 233-243	6
377	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <b>2018</b> , 11, 429-440	71
376	Genetic Complexity of Early-Onset Alzheimer's Disease. <b>2018</b> , 29-50	6
375	Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion. <b>2018</b> , 55, 8355-8373	5
374	Translational Research in Alzheimer's and Prion Diseases. <b>2018</b> , 62, 1247-1259	4
373	βAmyloid Prions and the Pathobiology of Alzheimer's Disease. <b>2018</b> , 8,	44
372	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. <b>2018</b> , 83, 447-455	62
371	Innate immunity in Alzheimer's disease: the relevance of animal models?. <b>2018</b> , 125, 827-846	10
370	Untangling Genetic Risk for Alzheimer's Disease. <b>2018</b> , 83, 300-310	101
369	Distinct βSynuclein strains and implications for heterogeneity among βSynucleinopathies. <b>2018</b> , 109, 209-218	87
368	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <b>2018</b> , 19, 244-328	148
367	Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. <b>2018</b> , 114, 3-9	45
366	Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology. <b>2018</b> , 128, 482-491	23
365	Making the final cut: pathogenic amyloid-βpeptide generation by βsecretase. <b>2018</b> , 2, 292-310	55
364	Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity. <b>2018</b> , 9, 4780	25
363	A Novel Transgenic Rat Model of Robust Cerebral Microvascular Amyloid with Prominent Vasculopathy. <b>2018</b> , 188, 2877-2889	17
362	Somatic APP gene recombination in Alzheimer's disease and normal neurons. <b>2018</b> , 563, 639-645	134
361	Genomics: New Light on Alzheimer's Disease Research. <b>2018</b> , 19,	10

360	Increased Insoluble Amyloid- $\beta$ Induces Negligible Cognitive Deficits in Old AppNL/NL Knock-In Mice. <b>2018</b> , 66, 801-809	5
359	Zebrafish: an emerging real-time model system to study Alzheimer's disease and neurospecific drug discovery. <b>2018</b> , 4, 45	80
358	The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease. <b>2018</b> , 8,	18
357	ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease. <b>2018</b> , 293, 18434-18443	20
356	Neuro-protective effects of aloperine in an Alzheimer's disease cellular model. <b>2018</b> , 108, 137-143	17
355	Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy. <b>2018</b> , 143, 1-9	21
354	Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of A $\beta$ plaque pathology. <b>2018</b> , 15, 256	19
353	Degradation of amyloid $\beta$ peptide by neprilysin expressed from Borna disease virus vector. <b>2018</b> , 62, 467	6
352	Early Detection of A Deposition in the 5xFAD Mouse by Amyloid PET. <b>2018</b> , 2018, 5272014	13
351	Up-regulation of NSP3 by Oligomeric A $\beta$ Accelerates Neuronal Death Through Cas-independent Rap1A Activation. <b>2018</b> , 386, 182-193	
350	Phosphatidylethanolamine-binding protein 1 protects CA1 neurons against ischemic damage via ERK-CREB signaling in Mongolian gerbils. <b>2018</b> , 118, 265-274	7
349	Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer's disease with PET imaging agents F-flutemetamol and F-florbetaben. <b>2018</b> , 19, 45	9
348	The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. <b>2018</b> , 19,	79
347	Repositioning Microtubule Stabilizing Drugs for Brain Disorders. <b>2018</b> , 12, 226	35
346	Generation of a human induced pluripotent stem cell line (LL008 1.4) from a familial Alzheimer's disease patient carrying a double KM670/671NL (Swedish) mutation in APP gene. <b>2018</b> , 31, 181-185	5
345	Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?. <b>2018</b> , 77, 855-870	27
344	Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion. <b>2018</b> , 14, 1129-1154	62
343	The Role of Methylated Circulating Nucleic Acids as a Potential Biomarker in Alzheimer's Disease. <b>2019</b> , 56, 2440-2449	8

342	A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP ECTFs, Not A $\beta$ 2019, 104, 256-270.e5	89
341	Targeting Synaptic Plasticity in Experimental Models of Alzheimer's Disease. 2019, 10, 778	31
340	Mouse induced pluripotent stem cells-derived Alzheimer's disease cerebral organoid culture and neural differentiation disorders. 2019, 711, 134433	12
339	Genetics, Ageing and Human Health. 2019, 193-209	
338	Diseases of the nERVous system: retrotransposon activity in neurodegenerative disease. 2019, 10, 32	53
337	Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid Fibrils. 2019, 14, e0219465	7
336	Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer's disease model mice. 2019, 14, e0219691	6
335	Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson's and Alzheimer's Diseases. 2019, 20,	5
334	Novel amyloid precursor protein mutation, Val669Leu ("Seoul APP"), in a Korean patient with early-onset Alzheimer's disease. 2019, 84, 236.e1-236.e7	7
333	Imbalance in the response of pre- and post-synaptic components to amyloidopathy. 2019, 9, 14837	7
332	Autocatalytic amplification of Alzheimer-associated A $\beta$ 2 peptide aggregation in human cerebrospinal fluid. 2019, 2, 365	28
331	History and progress of hypotheses and clinical trials for Alzheimer's disease. 2019, 4, 29	182
330	Overview of Transgenic Mouse Models for Alzheimer's Disease. 2019, 89, e81	37
329	PSEN1E9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. 2019, 13, 669-683	64
328	Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions. 2019, 10, 4303-4318	48
327	Genetic Analyses of Alzheimer's Disease in China: Achievements and Perspectives. 2019, 10, 890-901	12
326	Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model. 2019, 70, S239-S254	10
325	Editing the Central Nervous System Through CRISPR/Cas9 Systems. 2019, 12, 110	20



324	Processing of Mutant $\beta$ Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer's Disease. <b>2019</b> , 10, 383-403	19
323	$\beta$ Induced vulnerability propagates via the brain's default mode network. <b>2019</b> , 10, 2353	39
322	Longitudinal assessment of the neuroanatomical consequences of deep brain stimulation: Application of fornical DBS in an Alzheimer's mouse model. <b>2019</b> , 1715, 213-223	6
321	$\beta$ Sheet secondary structure in amyloid $\beta$ peptide drives aggregation and toxicity in Alzheimer's disease. <b>2019</b> , 116, 8895-8900	70
320	Santacruzamate A Ameliorates AD-Like Pathology by Enhancing ER Stress Tolerance Through Regulating the Functions of KDELR and Mia40-ALR and. <b>2019</b> , 13, 61	5
319	Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. <b>2019</b> , 10, 189	7
318	BACE-1 and $\beta$ Secretase as Therapeutic Targets for Alzheimer's Disease. <b>2019</b> , 12,	49
317	The vexing complexity of the amyloidogenic pathway. <b>2019</b> , 28, 1177-1193	13
316	Systemic LPS-induced $\beta$ olubilization and clearance in $\beta$ BP-transgenic mice is diminished by heparanase overexpression. <b>2019</b> , 9, 4600	6
315	Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies. <b>2019</b> , 20,	20
314	Alzheimer $\beta$ Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAK $\beta$ Neurons by Secretion. <b>2019</b> , 13, 452-477	10
313	Disease Pathway Cut for Multi-Target drugs. <b>2019</b> , 20, 74	5
312	Epigenome-Wide DNA Methylation and Histone Modification of Alzheimer's Disease. <b>2019</b> , 131-148	
311	Ovarian Hormone-Dependent Effects of Dietary Lipids on APP/PS1 Mouse Brain. <b>2019</b> , 11, 346	3
310	Anti-Amyloidogenic Effects of Asarone Derivatives From Leaves against Beta-Amyloid Aggregation and Nitric Oxide Production. <b>2019</b> , 24,	8
309	Emerging roles of N- and C-terminally truncated $\beta$ species in Alzheimer's disease. <b>2019</b> , 23, 991-1004	24
308	New evolutions in the BACE1 inhibitor field from 2014 to 2018. <b>2019</b> , 29, 761-777	44
307	Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation. <b>2019</b> , 398, 107-116	5

306	Translating Alzheimer's disease-associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. <b>2019</b> , 74, 135-146	16
305	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <b>2019</b> , 151, 417-434	10
304	Sex-biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: A multi-omic analysis. <b>2019</b> , 527, 462-475	35
303	Chronic Amyloid $\beta$ Oligomer Infusion Evokes Sustained Inflammation and Microglial Changes in the Rat Hippocampus via NLRP3. <b>2019</b> , 405, 35-46	15
302	Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid $\beta$ Associated Alzheimer's Disease in Mice. <b>2020</b> , 40, 1581-1593	24
301	NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. <b>2020</b> , 73, 723-739	16
300	Traffic-related air pollutants (TRAP-PM) promote neuronal amyloidogenesis through oxidative damage to lipid rafts. <b>2020</b> , 147, 242-251	39
299	The Regulatory Functionality of Exosomes Derived from hUMSCs in 3D Culture for Alzheimer's Disease Therapy. <b>2020</b> , 16, e1906273	34
298	Enhanced amyloid- $\beta$ generation by $\beta$ secretase complex in DRM microdomains with reduced cholesterol levels. <b>2020</b> , 29, 382-393	2
297	Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. <b>2020</b> , 16, 30-42	171
296	Circular RNA Encoded Amyloid Beta peptides-A Novel Putative Player in Alzheimer's Disease. <b>2020</b> , 9,	11
295	The influence of A $\beta$ dependent and independent pathways on TDP-43 proteinopathy in Alzheimer's disease: a possible connection to LATE-NC. <b>2020</b> , 95, 161-167	0
294	CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review. <b>2020</b> , 9, 419-434	11
293	Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid- $\beta$ In Brain. <b>2020</b> , 11, 4460-4468	7
292	Amyloid $\beta$ Peptide Increases Mitochondria-Endoplasmic Reticulum Contact Altering Mitochondrial Function and Autophagosome Formation in Alzheimer's Disease-Related Models. <b>2020</b> , 9,	12
291	Alix and Syntenin-1 direct amyloid precursor protein trafficking into extracellular vesicles. <b>2020</b> , 21, 58	11
290	Axonal Degeneration in AD: The Contribution of A $\beta$ and Tau. <b>2020</b> , 12, 581767	9
289	Dynamic changes in the brain protein interaction network correlates with progression of A $\beta$ 2 pathology in Drosophila. <b>2020</b> , 10, 18517	2

288	The role of prion strain diversity in the development of successful therapeutic treatments. <b>2020</b> , 175, 77-119	1
287	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1. <b>2020</b> , 15, 53	18
286	Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid- $\beta$ plaques. <b>2020</b> , 8, 212	5
285	Mechanisms of neurodegeneration - Insights from familial Alzheimer's disease. <b>2020</b> , 105, 75-85	15
284	Amyloidogenic processing of amyloid $\beta$ protein precursor (APP) is enhanced in the brains of alcadein B-deficient mice. <b>2020</b> , 295, 9650-9662	3
283	Shifting paradigms: The central role of microglia in Alzheimer's disease. <b>2020</b> , 143, 104962	25
282	Effects of obesity on hippocampus function: Synaptic plasticity hypothesis. <b>2020</b> , 19, 100246	3
281	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. <b>2020</b> , 76, 941-953	3
280	Real-time nanoscale organization of amyloid precursor protein. <b>2020</b> , 12, 8200-8215	10
279	New BACE1 Chimeric Peptide Inhibitors Selectively Prevent APP- $\beta$ Cleavage Decreasing Amyloid- $\beta$ Production and Accumulation in Alzheimer's Disease Models. <b>2020</b> , 76, 1317-1337	4
278	Sorting Out the Role of the in Alzheimer's Disease. <b>2020</b> , 4, 123-140	7
277	Genetic Dissection of Alzheimer's Disease Using Models. <b>2020</b> , 21,	10
276	Genetic architecture of neurodegenerative dementias. <b>2020</b> , 168, 108014	3
275	Behavioural and psychological symptoms of dementia in mouse models of Alzheimer's disease-related pathology. <b>2020</b> , 112, 634-647	25
274	Altered dorsal CA1 neuronal population coding in the APP/PS1 mouse model of Alzheimer's disease. <b>2020</b> , 10, 1077	3
273	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. <b>2020</b> , 32, 1188-1236	27
272	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. <b>2020</b> , 2020, 7039138	27
271	Diverse roles of Synaptotagmin-7 in regulating vesicle fusion. <b>2020</b> , 63, 42-52	6

270	Peroxidase activity of heme bound amyloid $\beta$ peptides associated with Alzheimer's disease. <b>2020</b> , 56, 4505-4518	10
269	Conformational Characterization of Native and L17A/F19A-Substituted Dutch-Type $\beta$ Amyloid Peptides. <b>2020</b> , 21,	3
268	The $\beta$ Secretase BACE1 in Alzheimer's Disease. <b>2021</b> , 89, 745-756	107
267	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). <b>2021</b> , 31, 25-52	9
266	Early detection and personalized medicine: Future strategies against Alzheimer's disease. <b>2021</b> , 177, 157-173	1
265	$\beta$ Amyloid: The known unknowns. <b>2021</b> , 65, 101212	13
264	Singular cases of Alzheimer's disease disclose new and old genetic "acquaintances". <b>2021</b> , 42, 2021-2029	2
263	Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease. <b>2021</b> , 97, 129-143	3
262	Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. <b>2021</b> , 46, 98-115	18
261	Directly Reprogrammed Neurons Express MAPT and APP Splice Variants Pertinent to Ageing and Neurodegeneration. <b>2021</b> , 58, 2075-2087	2
260	Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model. <b>2021</b> , 11, 8129-8142	13
259	Is $\beta$ Secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. <b>2021</b> , 296, 100489	15
258	Genetic Aspects of Early-Onset Alzheimer's Disease. <b>2021</b> , 29-39	
257	Mitochondrial fission is a critical modulator of mutant APP-induced neural toxicity. <b>2021</b> , 296, 100469	3
256	Exome-wide age-of-onset analysis reveals exonic variants in ERN1 and SPPL2C associated with Alzheimer's disease. <b>2021</b> , 11, 146	1
255	Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model. <b>2021</b> , 69, 1852-1881	12
254	Entering a new era of quantifying glutamate clearance in health and disease. <b>2021</b> , 99, 1598-1617	2
253	Mind the Gap: Mitochondria and the Endoplasmic Reticulum in Neurodegenerative Diseases. <b>2021</b> , 9,	7

252	Systematic analysis of brain lactate and pH levels in 65 animal models related to neuropsychiatric conditions.	2
251	Screening Platform Based on Inductively Coupled Plasma Mass Spectrometry for $\beta$ Site Amyloid Protein Cleaving Enzyme 1 (BACE1) Inhibitors. <b>2021</b> , 12, 1093-1099	2
250	Analysis of Polymorphisms in microRNAs Deregulated in Alzheimer Disease. <b>2021</b> , 15, 631852	1
249	Amyloid Structural Changes Studied by Infrared Microspectroscopy in Bigenic Cellular Models of Alzheimer's Disease. <b>2021</b> , 22,	3
248	Pulsed Hydrogen-Deuterium Exchange Reveals Altered Structures and Mechanisms in the Aggregation of Familial Alzheimer's Disease Mutants. <b>2021</b> , 12, 1972-1982	1
247	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. <b>2021</b> , 22,	6
246	NADH Fluorescence Lifetime Imaging Microscopy Reveals Selective Mitochondrial Dysfunction in Neurons Overexpressing Alzheimer's Disease-Related Proteins. <b>2021</b> , 8, 671274	1
245	Dietary intervention with edible medicinal plants and derived products for prevention of Alzheimer's disease: A compendium of time-tested strategy. <b>2021</b> , 81, 104463	3
244	PEA $\beta$ triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease. <b>2021</b> , 22,	1
243	Refining the amyloid $\beta$ peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. <b>2021</b> , 159, 234-257	0
242	CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. <b>2021</b> ,	3
241	Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice. <b>2021</b> ,	5
240	Suppression of amyloid- $\beta$ secretion from neurons by cis-9, trans-11-octadecadienoic acid, an isomer of conjugated linoleic acid. <b>2021</b> , 159, 603-617	0
239	The Amyloid- $\beta$ Pathway in Alzheimer's Disease. <b>2021</b> ,	63
238	Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer's Disease Associates with Upregulated Angiopoietin and Downregulated Hypoxia-Inducible Factor. <b>2021</b> , 83, 1651-1663	0
237	Kif11 overexpression rescues cognition, long-term potentiation, and spine defects in mouse and cell models of Alzheimer's disease.	
236	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. <b>2021</b> , 64, 14175-14191	4
235	Pregabalin Treatment does not Affect Amyloid Pathology in 5XFAD Mice. <b>2021</b> , 18, 283-297	1

234	Cholinergic Deep Brain Stimulation for Memory and Cognitive Disorders. <b>2021</b> , 83, 491-503	1
233	Human-Soybean Allergies: Elucidation of the Seed Proteome and Comprehensive Protein-Protein Interaction Prediction. <b>2021</b> , 20, 4925-4947	1
232	Lemur tail kinase 1 (LMTK1) regulates the endosomal localization of $\beta$ -secretase BACE1. <b>2021</b> ,	1
231	Molecular Mechanisms Underlying Pathogenic Missense Mutations.	0
230	Metabolism of amyloid proteins. <b>1996</b> , 199, 104-113; discussion 113-8	3
229	Early Onset Familial Alzheimer's Disease: Is a Mutation Predictive of Pathology?. <b>2005</b> , 45-59	1
228	Protease Inhibitors and their Involvement in Neurological Disorders. <b>2007</b> , 591-624	2
227	Cognitive Impairment in Transgenic A $\beta$ and Tau Models of Alzheimer's Disease. <b>2007</b> , 77-91	1
226	Autosomal Dominant Alzheimer's Disease: Underlying Causes. <b>2014</b> , 27-47	2
225	Familial Amyotrophic Lateral Sclerosis and Alzheimer's Disease. <b>1998</b> , 145-159	6
224	Molecular Pathobiology of Alzheimer's Disease. <b>1994</b> , 209-238	1
223	Use of PET Technique to Monitor Effect of Drugs in Alzheimer Disease Treatment. <b>1994</b> , 405-412	4
222	Therapeutic Strategies in Alzheimer's Disease. <b>1994</b> , 485-492	1
221	A Role for Acetylcholine and Acetylcholinesterase in the Regulation of Neurite Outgrowth. <b>1995</b> , 455-461	1
220	Etiological Clues from Gene Defects Causing Early Onset Familial Alzheimer's Disease. <b>1997</b> , 1-19	4
219	Signaling by $\beta$ -Amyloid Precursor Protein. <b>1998</b> , 197-220	1
218	A $\beta$ Infusion and Related Models of Alzheimer Dementia. <b>2011</b> , 347-370	5
217	The A $\beta$ entric Pathway of Alzheimer's Disease. <b>2007</b> , 5-36	1

216	Therapeutic Potential of Small Interfering RNA for Brain Diseases. <b>2009</b> , 275-295	1
215	Proteolytic Processing of the Amyloid Precursor Protein of Alzheimer's Disease. <b>2000</b> , 359-374	2
214	Molecular Genetics of the Presenilins in Alzheimer's Disease. <b>1998</b> , 1-10	2
213	The APP and PS1/2 Mutations Linked to Early Onset Familial Alzheimer's Disease Increase the Extracellular Concentration of A $\beta$ 2(43). <b>1998</b> , 27-33	1
212	Alzheimer's Disease and Hemorrhagic Stroke: Their Relationship to A $\beta$ 4 Amyloid Deposition. <b>1995</b> , 37-48	3
211	Amyloid in Alzheimer's Disease and Animal Models. <b>1994</b> , 156-168	1
210	The Role of the Extracellular Matrix in Regulating the Function of the Amyloid Protein Precursor of Alzheimer's Disease. <b>1994</b> , 65-75	1
209	The Biological Function of Amyloid A $\beta$ 4 Protein Precursor. <b>1994</b> , 90-99	4
208	Demenz. <b>2017</b> , 1377-1465	1
207	Presenilins and Alzheimer's disease: the role of A $\beta$ 2. <b>1998</b> , 181-184	2
206	Pathology of familial Alzheimer's disease with Lewy bodies. <b>1997</b> , 51, 121-35	12
205	APOE Genotype in Relation to Sporadic and Alzheimer-Related CAA. <b>2000</b> , 81-102	8
204	Amyloid- $\beta$ and Tau at the Crossroads of Alzheimer's Disease. <b>2019</b> , 1184, 187-203	48
203	Genetic Markers of Alzheimer's Disease. <b>2019</b> , 1192, 27-52	23
202	Aging-Related Memory Disorders. <b>2003</b> , 337-366	1
201	Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D. <b>1994</b> , 269, 18422-18428	36
200	Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. <b>1994</b> , 269, 17741-17748	224
199	Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase.. <b>1994</b> , 269, 3111-3116	71

198	Metabolism of the Swedish amyloid precursor protein variant in Madin-Darby canine kidney cells.. <b>1994</b> , 269, 30966-30973	41
197	Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.. <b>1993</b> , 268, 22959-22962	88
196	Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A. <b>2001</b> , 7, 381-91	19
195	Molecular genetics of familial Alzheimer disease. <b>1998</b> , 315, 266-72	17
194	Somatostatin receptor subtypes 1 and 4 redundantly regulate neprilysin, the major amyloid-beta degrading enzyme in brain.	1
193	Endosulfine regulates amyloid $\beta$ 2 via the modulation of neprilysin activity.	0
192	Genome-Encoded Cytoplasmic Double-Stranded RNAs, Found in C9ORF72 ALS-FTD Brain, Provoke Propagated Neuronal Death.	4
191	The role of A $\beta$ circRNA in Alzheimer's disease: alternative mechanism of A $\beta$ biogenesis from A $\beta$ circRNA translation.	3
190	Theiler's virus as a vector for foreign gene delivery. <b>1995</b> , 69, 3171-5	14
189	Neuro-pathological Implications of Amyloid Protein: An Update. 2,	1
188	Proteolytic processing and cell biological functions of the amyloid precursor protein. <b>2000</b> , 113, 1857-1870	418
187	The integration site of the APP transgene in the J20 mouse model of Alzheimer's disease. <b>2017</b> , 2, 84	11
186	FAD mutations in amyloid precursor protein do not directly perturb intracellular calcium homeostasis. <b>2010</b> , 5, e11992	13
185	The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. <b>2003</b> , 23, 2086-92	220
184	Raf kinase inhibitory protein (RKIP): functional pleiotropy in the mammalian brain. <b>2014</b> , 19, 505-16	16
183	Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex. <b>2016</b> , 8, 3430-3449	8
182	The genetics of Alzheimer's disease. <b>2014</b> , 9, 535-51	103
181	Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. <b>2020</b> , 21, 148-166	7



180	Genetic Variants and Oxidative Stress in Alzheimer's Disease. <b>2020</b> , 17, 208-223	12
179	Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders. <b>2020</b> , 17, 238-258	2
178	The Links between Cardiovascular Diseases and Alzheimer's Disease. <b>2021</b> , 19, 152-169	8
177	Genetic studies in Alzheimer's disease. <b>2003</b> , 5, 17-26	22
176	Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease. <b>2018</b> , 61, 195-208	19
175	Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer's disease. <b>2017</b> , 66, 553-565	55
174	Neuroprotection induced by Nav $\beta$ -knockdown in APP/PS1 transgenic neurons is associated with NEP regulation. <b>2019</b> , 20, 2002-2011	3
173	SUMO modulation of protein aggregation and degradation. <b>2015</b> , 2, 382-410	8
172	Genetics, transcriptomics, and proteomics of Alzheimer's disease. <b>2006</b> , 67, 652-70	58
171	Alzheimer's disease: a clearer definition of the genetic components. <b>1994</b> , 160, 243-244	4
170	Diets with Higher $\beta\beta/\beta\beta$ Ratios Show Differences in Ceramides and Fatty Acid Levels Accompanied by Increased Amyloid-Beta in the Brains of Male APP/PS1 Transgenic Mice. <b>2021</b> , 22,	1
169	The Swedish dilemma - the almost exclusive use of APP <sup>swe</sup> -based mouse models impedes adequate evaluation of alternative $\beta$ secretases. <b>2021</b> , 119164	1
168	Genetics of Alzheimer's disease--routes to the pathophysiology. <b>2000</b> , 59, 155-61	2
167	Clinical and Genetic Aspects of Hereditary Cerebral Hemorrhage with Amyloidosis Dutch Type (HCHW A-D). <b>2000</b> , 103-119	1
166	Mechanism of neuron death in Alzheimer's disease. <b>2001</b> , 201-207	
165	Lessons in familial Alzheimer's disease. <b>2001</b> , 259-265	1
164	Genetically Engineered Models of Human Age-Related Neurodegenerative Diseases. <b>2001</b> , 387-406	1
163	Molecular Genetics and Molecular Biology of Alzheimer's Disease. <b>2001</b> , 1187-1218	

- 162 The Value of Transgenic Models for the Study of Neurodegenerative Diseases. **2001**, 67-86
- 161 Genetics of early-onset Alzheimer disease. **2001**, 153-165
- 160 Screening for PS1 mutations in a referral-based late-onset AD cases in Saudi Arabia. **2003**, 3, 209-213 1
- 159 Pathological Detection of AB and APP in Brain. **2004**,
- 158 Biochemical Characterization of Amyloid Precursor Protein. **2004**,
- 157 Creating APP Transgenic Lines in Mice. **2004**,
- 156 Single Nucleotide Polymorphism Associated with Late-onset Alzheimer's Disease. **2005**, 5, 275-279 2
- 155 Beta-amyloid precursor protein and early-onset Alzheimer's disease. **1996**, 199, 170-80
- 154 Prospects for Neural Stem Cell Therapy of Alzheimer Disease. **2011**, 337-348
- 153 Pathological Validation of Animal Models of Dementia. **2011**, 99-141
- 152 The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: II Experimental Evidence and Clinical Studies. **2011**, 02, 239-267
- 151 Demenz. **2011**, 1240-1319
- 150 The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies. **2011**, 02, 397-409
- 149 Gènétique des formes autosomiques dominantes de maladie d'Alzheimer. **2013**, 157-174
- 148 APP Gene Mutations in Familial Alzheimer's Disease in Sweden. **1981**, 209-215
- 147 Patent Evaluation: A Transgenic Animal Model for Alzheimer's Disease. **1992**, 2, 1869-1872
- 146 Molecular biology and pathology of Alzheimer's disease. **1993**, 61-73
- 145 References. **1993**, 87, 59-70

144 Beta Amyloid (A $\beta$ ) as a Therapeutic Target in Alzheimer's Disease. **1994**, 49-53

143 The Diverse Molecular Nature of Inherited Alzheimer's Disease. **1994**, 181-189

142 The Roles of Zinc and Copper in the Function and Metabolism of the Amyloid Protein Precursor Superfamily. **1994**, 169-180

141 Production of Amyloid  $\beta$  Protein from Normal and Mutated Amyloid  $\beta$  Protein Precursors. **1994**, 36-45

140 Genetic Variability and Alzheimer's Disease. **1994**, 190-198

139 Glutamate, beta-amyloid precursor proteins, and calcium mediated neurofibrillary degeneration. **1994**, 44, 29-45

13

138 Mechanism of Cerebral Amyloidosis in Alzheimer's Disease. **1994**, 46-59

137 Genetic Defects in Early Onset Alzheimer's Disease and Related Disorders. **1994**, 199-208

136 Amyloid Deposition as the Central Event in the Etiology and Pathogenesis of Alzheimer's Disease. **1994**, 23-27

1

135 Processing of Alzheimer A $\beta$  Amyloid Precursor Protein: Cell Biology, Regulation, and Role in Alzheimer's Disease. **1994**, 100-120

134 Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. **1994**, 285-293

1

133 The molecular genetics of Alzheimer's disease. **1994**, 4, 92-109

132 Post-translational control of the amyloid  $\beta$  protein precursor processing. **1995**, 99-114

131 Cellular and animal models of amyloid  $\beta$  protein amyloidosis. **1995**, 183-192

130 Neurotoxicity of amyloid  $\beta$  protein and the amyloid  $\beta$  protein precursor. **1995**, 145-165

1

129 Alzheimer's Disease. **1996**, 389-428

128 In Vivo Biology of Amyloid Precursor Protein/Amyloid Precursor-like Proteins and Transgenic Animal Models of Alzheimer's Disease. **1996**, 61-76

127 Genetic Factors Contributing to Cardiovascular Disease that may affect Endothelial Structure and Function: The Role of Proteins involved in Lipoprotein Transport. **1996**, 69-128

- 126 Regulation of Amyloid  $\beta$  Protein Precursor Processing by Cell Surface Receptor Ligands and Second Messengers. **1996**, 93-107
- 125 Molecular Processing Pathways of  $\beta$  Amyloid Precursor Protein: Therapeutic Implications. **1996**, 77-92
- 124 Regulation der APP Prozessierung durch Neurotransmitterrezeptoren: Implikationen für die Entwicklung neuer Therapien der Alzheimer-Demenz. **1996**, 17-23
- 123 Neuroprotective Signal Transduction Pathways of sAPP and TNF. **1997**, 165-172
- 122 Gehirn und Nervensystem. **1997**, 299-314
- 121 Etiological Considerations. **1997**, 153-185
- 120 From prion diseases to Alzheimer's disease. **1997**, 49, 135-44 4
- 119 The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. **1997**, 49, 23-31 6
- 118 Metabolism and Function of Presenilin 1. **1998**, 35-47
- 117 Molecular Genetics of Alzheimer's Disease. **1998**, 901-906 0
- 116 Presenilin 2  $\beta$ APP Interactions. **1998**, 59-70 1
- 115 Regulation of APP Metabolism by Protein Phosphorylation. **1998**, 133-140
- 114 Transgenic Models of Amyotrophic Lateral Sclerosis and Alzheimer's Disease. **1998**, 107-123
- 113 Role of Apolipoprotein E in Alzheimer's Disease. **1998**, 179-209 3
- 112 Anthracyclines and Amyloidosis. **1998**, 197-204
- 111 Molekulargenetik und Molekularbiologie der Alzheimer-Krankheit. **1999**, 117-165
- 110 Alzheimer's Disease and Genetically Engineered Animal Models. **1999**, 187-214
- 109 Genetik der Alzheimer Demenz. **1999**, 33-54 0

108 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351

107 QSAR Models towards Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. **2015**, 354-399

106 Demenz. **2016**, 1-89

105 QSAR Models towards Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease. **2017**, 591-636

104 Neuro-pathological Implications of  $\beta$ Amyloid Protein: An Update. **2018**, 2, 02006

103 Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and presynaptic plasticity.

102 Dynamic changes in the brain protein interaction network correlates with progression of  $A\beta$ 2 pathology in Drosophila.

101 A Novel Cell-based  $\beta$ secretase Enzymatic Assay for Alzheimer's Disease. **2019**, 16, 128-134

100 La g n tique de la maladie d'Alzheimer. **2019**, 19, 83-90

1

99 News from Mars: Two-Tier Paradox, Intracellular PCR, Chimeric Junction Shift, Dark Matter mRNA and Other Remarkable Features of Mammalian RNA-Dependent mRNA Amplification. Implications for Alzheimer's Disease, RNA-Based Vaccines and mRNA Therapeutics. **2021**, 2, 131-173

1

98 Imbalance in the response of pre- and post-synaptic components to amyloidopathy.

97 Mitochondrial fission is a critical modulator of mutant APP-induced neural toxicity.

96 Exome-wide age-of-onset analysis reveals exonic variants in ERN1, TACR3 and SPPL2C associated with Alzheimer's disease.

95 Alzheimer's Disease: Etiology, Neuropathology and Pathogenesis. 1-22

5

94 Is It the Twilight of BACE1 Inhibitors?. **2021**, 19, 61-77

2

93 Genomics of Alzheimer's disease. **2020**, 3-18

92 Alzheimer model 5xfad mice and applications to dementia. **2020**, 833-847

91 Somatostatin-evoked  $A\beta$  catabolism in the brain: Mechanistic involvement of  $\beta$ endosulfine-K channel pathway. **2021**,

1

90	Early onset Alzheimer's disease in a South American pedigree from Argentina. <b>1995</b> , 91, 6-13	0
89	Intraneuronal A $\beta$ and Alzheimer's Disease. <b>2008</b> , 297-304	
88	Co-expression of FTDP-17 Human Tau and GSK-3 $\beta$ (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration. <b>2008</b> , 337-342	
87	Suppression of amyloid- $\beta$ secretion from neurons by cis-9, trans-11-octadecadienoic acid, an isomer of conjugated linoleic acid.	
86	Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence. <b>1995</b> , 14, 4932-8	61
85	The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein. <b>1996</b> , 15, 5218-29	43
84	Chromosome 14 and late-onset familial Alzheimer disease (FAD). <b>1993</b> , 53, 619-28	45
83	Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. <b>1995</b> , 56, 332-5	15
82	Carboxyl-terminal fragments of beta-amyloid precursor protein bind to microtubules and the associated protein tau. <b>1997</b> , 151, 265-71	28
81	Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. <b>1996</b> , 148, 259-65	87
80	High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice. <b>1996</b> , 149, 219-27	56
79	Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. <b>1993</b> , 142, 17-24	44
78	A population-based study of familial Alzheimer disease: linkage to chromosomes 14, 19, and 21. <b>1994</b> , 55, 714-27	28
77	Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. <b>1994</b> , 55, 1159-65	229
76	Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. <b>1997</b> , 3, 695-707	46
75	Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. <b>2006</b> , 2, 154-60	11
74	Comparable dimerization found in wildtype and familial Alzheimer's disease amyloid precursor protein mutants. <b>2013</b> , 2, 15-28	6
73	Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture. <b>1995</b> , 29, 412-8	3

72	Molecular Mechanisms in Alzheimer's Disease. <b>2004</b> , 15, 100-103	1
71	Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease. <b>2022</b> , 69-151	0
70	Neurodegenerative diseases. <b>2022</b> , 1-67	
69	CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. <b>2021</b> , 1	4
68	An insight into Alzheimer's disease and its on-setting novel genes. <b>2021</b> , 57,	2
67	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. <b>2021</b> ,	0
66	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. <b>2021</b> , 15, 339-352	
65	Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock-in rats with humanizing mutations in the A $\beta$ -coding region of App.	
64	Sodium-calcium exchanger isoform-3 targeted Withania somnifera (L.) Dunal therapeutic intervention ameliorates cognition in the 5xFAD mouse model of Alzheimer's disease.. <b>2022</b> , 12, 1537	
63	Chronic effects of blast injury on the microvasculature in a transgenic mouse model of Alzheimer's disease related A $\beta$ amyloidosis.. <b>2022</b> , 19, 5	0
62	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's Disease.. <b>2022</b> ,	2
61	Physiology and pharmacology of amyloid precursor protein.. <b>2022</b> , 235, 108122	4
60	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.. <b>2022</b> , 23, 99	0
59	Increased Expression of KIF11/Kinesin5 Offsets Alzheimer A $\beta$ -Mediated Toxicity and Cognitive Dysfunction in Cell Culture, Mice, and Humans.	
58	Introduction. <b>2022</b> , 1-14	
57	rTg-D: A novel transgenic rat model of cerebral amyloid angiopathy Type-2. <b>2022</b> , 3, 100133	
56	Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer's Disease.. <b>2022</b> , 14, 805063	
55	Alzheimer's disease amyloid- $\beta$ pathology in the lens of the eye.. <b>2022</b> , 108974	1

54	Recent Advances in the Modeling of Alzheimer's Disease.. <b>2022</b> , 16, 807473	4
53	Alzheimer's disease - the journey of a healthy brain into organ failure.. <b>2022</b> , 17, 18	3
52	Complement System in Alzheimer's Disease.. <b>2021</b> , 22,	3
51	High-Phytate Diets Increase Amyloid $\beta$ Deposition and Apoptotic Neuronal Cell Death in a Rat Model.. <b>2021</b> , 13,	0
50	EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid- $\beta$ Production.. <b>2021</b> , 23,	2
49	$\beta$ Secretase structure and activity are modified by alterations in its membrane localization and ambient environment. <b>2021</b> ,	0
48	PTPRD and DCC Are Novel BACE1 Substrates Differentially Expressed in Alzheimer's Disease: A Data Mining and Bioinformatics Study.. <b>2022</b> , 23,	0
47	miR-23b-3p rescues cognition in Alzheimer's disease by reducing tau phosphorylation and apoptosis via GSK-3 $\beta$ signaling pathways.. <b>2022</b> , 28, 539-557	1
46	Second Sphere Interactions in Amyloidogenic Diseases.. <b>2022</b> ,	3
45	Amyloid- $\beta$ Oligomers: Multiple Moving Targets. <b>2022</b> , 2, 91-110	2
44	Biological activities of amyloid precursor protein. <b>1998</b> , 49, 7-27	1
43	The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer's disease. <b>2022</b> , 151, 113188	
42	Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. <b>2022</b> , 74, 600-629	5
41	Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches. 16,	0
40	Brain Amyloid- $\beta$ Accumulation in AD Mouse Models Modified by Their Altered Gene Expression in the Presence of Human apoE Isoforms Through Aging Process.	
39	Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. <b>2022</b> , 17,	1
38	Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease.	0
37	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. <b>2022</b> , 20, e3001694	3



- 36 Animal Models of Cognitive Deficits for Probiotic Treatment.
- 35 circRNA drives the formation and deposition of  $\beta$  amyloid plaques in the sporadic Alzheimer's disease.
- 34 Heme/Cu-oxygen intermediates of amyloid  $\beta$  peptides associated with Alzheimer's disease. **2022**,
- 33 Basics of amyloid  $\beta$  protein in Alzheimer's disease. **2022**, 73-89
- 32 Impact of cellular prion protein expression on disease progression and pathology in two mouse models of Alzheimer's disease.
- 31 Increased KIF11/Kinesin-5 expression offsets Alzheimer A $\beta$  mediated toxicity and cognitive dysfunction. **2022**, 105288
- 30 Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer's disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations. 14,
- 29 Glycosylated clusterin species facilitate A $\beta$  toxicity in human neurons. **2022**, 12,
- 28 Cathepsin D: Analysis of its potential role as an amyloid beta degrading protease. **2022**, 175, 105919
- 27 Familial Alzheimer disease mutation undermines axonal transport by enhancing dynactin recruitment to the APP motor assemblies.
- 26 A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. **2022**, 12, 2975
- 25 Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.
- 24 Enhanced activity of Alzheimer disease-associated variant of protein kinase C $\delta$  drives cognitive decline in a mouse model. **2022**, 13,
- 23 A $\beta$ 3 levels determine the onset of pathological amyloid deposition.
- 22 Rare Amyloid Precursor Protein Point Mutations Recapitulate Worldwide Migration and Admixture in Healthy Individuals: Implications for the Study of Neurodegeneration. **2022**, 23, 15871
- 21 Genetica della malattia di Alzheimer. **2022**, 22, 1-8
- 20 Accumulation of amyloid- $\beta$  in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging. **2022**,
- 19 Translational potential of synaptic alterations in Alzheimer's disease patients and App knock-in mice.

18	Experimental approaches for altering the expression of Abeta-degrading enzymes.	1
17	Plasma biomarker profiles in autosomal dominant Alzheimer's disease.	0
16	Distinct effects of SDC3 and FGFR1 on selective neurodegeneration in AD and PD. <b>2023</b> , 37,	0
15	TRPV4 mRNA is elevated in the caudate nucleus with NPH but not in Alzheimer's disease. 13,	0
14	The US9-Derived Protein gPTB9TM Modulates APP Processing Without Targeting Secretase Activities.	0
13	Comprehensive genetic screening of early-onset dementia patients in an Austrian Cohort-Suggesting new disease-contributing genes.	0
12	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. <b>2023</b> , 229, 109478	0
11	Moesin is an effector of tau-induced actin overstabilization, cell cycle activation, and neurotoxicity in Alzheimer's disease. <b>2023</b> , 26, 106152	0
10	Mitofusin-2: Functional switch between mitochondrial function and neurodegeneration. <b>2023</b> , 69, 116-129	1
9	The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. 3,	0
8	The Role of Heme and Copper in Alzheimer's Disease and Type 2 Diabetes Mellitus. <b>2023</b> , 3, 657-681	0
7	The structural mechanism of MCIA complex assembly links mitochondrial redox pathways.	0
6	Early mitochondrial dysfunction proceeds neuroinflammation, synaptic alteration, and autophagy impairment in hippocampus of Appknock-in Alzheimer mouse models.	0
5	Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid- $\beta$ in hAPP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition. <b>2023</b> , 1-14	0
4	Deficits in mitochondrial function and glucose metabolism seen in sporadic and familial Alzheimer's disease derived Astrocytes are ameliorated by increasing hexokinase 1 expression.	0
3	Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy.	0
2	RGS6 mediates exercise-induced recovery of hippocampal neurogenesis, learning, and memory in an Alzheimer's mouse model.	0
1	Vector enabled CRISPR gene editing - A revolutionary strategy for targeting the diversity of brain pathologies. <b>2023</b> , 487, 215172	0

